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ABSTRACT
E2F1-INDUCED EXPRESSION OF TRANSACTIVATING
AND DOMINANT-NEGATIVE FORMS OF p73 TRANSCRIPTS
Ozgur KARAKUZU
M.S. in Molecular Biology and Genetics
Supervisor: Prof. Dr. Mehmet OZTURK
August 2002, 102 pages.
Cell cycle, one of the most important life processes, is controlled by a
regulated balance between proliferative and anti-proliferative signals. Dysregulation
of these signals leads to tumor development. Retinoblastoma (Rb) gene is the
principle regulator of the cell cycle. Rb was identified initially as a gene deleted in a
rare form of early child eye tumor, called retinoblastoma, and it was later shown to
be a tumor-suppressor. Cellular functions of Rb are inactivated in many cancer
types, either directly by Rb gene mutation, or indirectly by inactivation of the pRb
protein that is mediated by different viral oncogenes.  pRB exists in non-
proliferating (quiescent) cells as a complex with E2F transcription factors. Upon
phosphorylation of pRb by cyclin-dependent kinases, E2Fs are released and can
transactivate their target genes. E2F1, the first E2F to be identified, activates mostly
proliferative genes, but also anti-proliferative genes such as p14ARF that acts as an
inducer of p53 stabilization. In turn, p53 induces either cell cycle arrest or
programmed cell death (apoptosis). Recently, it was reported that E2F1 also induces
p53-independent apoptosis by transactivating the expression of the p53 homologue
p73 gene. However, p73 encodes not only apoptosis-inducing transciptionally
active(TA)-p73, but also dominant negative (DN)-p73 transcript forms which
antagonize TA-p73. Our aim was to investigate whether the E2F1 activates the
expression of TA-p73, DN-p73 or both. We over-expressed E2F1 and E2F4 in
different human cell lines, by transient transfection using appropriate expression
vectors, and analyzed p73 transcript levels by semi-quantitative RT-PCR. We
demonstrate that, in different cell lines, E2F1 induced the expression of not only
TA-p73, but also its two dominant-negative forms, namely p73Deltaexon2 and DN-
vp73. Time course studies indicated that TA-p73 and p73DeltaExon2 forms are
induced initially, and DN-p73 induction is delayed about 4 hours. Induced
expression of dominant-negative forms, in addition to transcriptionally active p73
transcripts by E2F1 may explain how some cancer cells are able to tolerate p73
activation in response to oncogenes such as E2F1.
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ÖZET
EF21 TRANSKRİPSİYON FAKTÖRÜ TARAFINDAN
p73’ÜN AKTİF VE DOMİNANT-NEGATİF TRANSKRİPT
FORMLARININ ENDÜKLENİŞİ
Özgür Karakuzu
Moleküler Biyoloji ve Genetik Yüksek Lisans
Tez Yöneticisi: Prof. Dr. Mehmet Öztürk
Ağustos 2002, 102 Sayfa
Yaşam için en önemli işlemler arasında yer alan hücre döngüsü, çoğaltıcı ve
çoğalmayı engelleyici uyarıların karşılıklı olarak dengelenmesi yolu ile denetlenir.
Bu uyarılardaki düzensizlik tümör gelişimine yolaçmaktadır. Retinoblastoma (Rb)
geni hücre döngüsünün ana düzenleyicidir. Bir çocukluk çağı göz tümörü olan
retinoblastomalarda delesyona uğrayan bir gen olaran ortaya çıkarılan Rb geninin,
tümör baskılayıcı bir gen olduğu sonradan belirlenmiştir. Rb geninin hücre işlevleri,
ya doğrudan mutasyonla, ya da dolaylı olarak pRb proteininin virüs onkogenlerince
etkisiz hale getirilmesiyle, bir çok tümör türünde kaybolmaktadır. pRB proteini,
çoğalmayan (dingin) hücrelerde, E2F transkipsiyon faktörleri ile birlikte bir
kompleks halinde bulunur. pRb’nin siklin-bağımlı kinazlar tarafından fosforlanması
üzerine, E2F’ler serbest kalır ve böylece hedef genlerini aktif hale getirebilir. İlk
belirlenen E2F olan E2F1, sıklıkla çoğaltıcı genleri uyarmakla birlikte, çoğalmayı
engelleyen genleri de, örneğin p53 proteinini stabilize eden p14ARF genini de
uyarabilir. Bunun sonucu olarak, p53 hücre döngüsünü durdurur veya programlı
hücre ölümüne (apoptoz) neden olur. Daha yakın bir zamanda, E2F1’in p53’den
bağımsız olarak ve bir p53 homoloğu olan p73 genini uyarma yolu ile de apoptoza
yol açtığı bildirildi. Ancak, p73, sadece apoptoz etkisi olan aktif (TA) p73 değil,
aynı zamanda TA-p73 antagonisti olan dominant negatif (DN) p73 transcript
formları da kodlayabilmektedir. Bu çalışmanın amacı E2F1’ın TA-p73’ü mü, DN-
p73’ü mü, yoksa her iki form birlikte mi uyardığını belirlemekti. Bu amaç
doğrultusunda, ekspresyon vektörleri ile geçici transfeksiyon yöntemini
uygulayarak, çeşitli insan hücre dizilerinde E2F1ve E2F4’ün ifade edilmesini
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sağladık ve yarı-kantitatif RT-PCR’la p73 transkript düzeylerini inceledik. Bu
çalışmalarımız, çeşitli insan hücrelerinde, E2F1’in sadece TA-p73’ü değil, ayrıca bu
molekülün dominant-negatif formlarını, yani p73Deltaexon2 ve DN-p73’ü de
uyardığını gösterdi. Zaman akışlı incelemelerle, önce TA-p73 ve p73DeltaExon2
formlarının uyarıldığını, DN-p73 uyarımının ise yaklaşık 4 saat sonra gerçekleştiğini
gözlemledik. E2F1 tarafından p73’ün TA formuna ek olarak dominant-negatif
formlarının da uyarılması, bazı kanser hücrelerinin E2F1 gibi onkogenlere yanıt
olarak geliştirilen p73 aktivasyonunu nasıl  tolere edebildiklerini açıklayabilir.
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1CHAPTER 1
INTRODUCTION
21.1        pRb/E2F PATHWAY
In physiological conditions, mammalian cells are found in different stages
such as quiescence (non-proliferation), proliferation and senescence. Cell
proliferation is governed by the cell cycle machinery. Cell cycle is regulated
strictly, and its dysregulation results in tumorigenesis. Cell cycle is controlled by
a finely tuned balance between proliferative and anti-proliferative signals. Cell
cycle is under the control of a family of protein kinases called cyclin-dependent
kinases (CDKs), activation of which is in a sequential manner during the cell
cycle (Sherr and Roberts, 1999). In order to be active, CDKs have to associate
with a group of activating proteins called cyclins. Actually there is always a
ubiquitous expression and pool of inactive CDKs in cells, but they need to
associate with cyclins to be active. Cell cycle is regulated by cellular levels of
cyclins. At different stages of cell cycle different couples of CDKs and cyclins
take role. For the entry into cell cycle, the step is the activation of CDK4 and
CDK6 in association with cyclin D. Activation of cyclin D/CDK4-6 complex
triggers the subsequent activation of CDK2, which then associates with cyclin E.
Following set of cyclin/kinase complex is the cyclin A/CDK2. Near to the end of
replication phase cyclin B/CDK1 (mitosis promoting factor) is activated and
mitosis starts. There are many pathways interfering and affecting regulation of
cell cycle. Dysregulation in the activities of cyclins and CDKs may lead to cancer
development, as it was shown by activating mutation of CDK4 and amplification
of cyclin D gene in some cancers (reviewed by Ortega et al. 2002).
The activities of cyclin/CDK complexes are regulated by cyclin dependent
kinase inhibitors (CKIs) including INK4 and Cip/Kip family of proteins.
p16INK4A, p15INK4B, p18INK4C and p19INK4D are the members of INK4 family and
their principle targets are CDK4 and CDK6, which induces the G1-S transition of
cell cycle.  The Cip/Kip family members, p21Cip1, p27Kip1 and p57Kip2 seem to
have dual roles. They negatively regulate cyclin E-cyclin A/CDK2 complexes,
whereas they have activating effect on cyclin D/CDK4-6.  Having dual roles for
cell cycle, Cip/Kip family proteins are not expected to have inactivating
mutations. However for INK4 family of proteins, there are cases of mutations and
epigenetic changes (de novo methylation) yielding in abnormal cell proliferation
3and tumor formation.  Figure 1 is a presentation of different regulators of cell
cycle.
Jeffrey M. Trimarchi and Jacqueline A. Lees, 2002
Figure 1:  Regulation of Cell cycle by proliferative and anti-proliferative signals
 The most important substrate of CDKs is the retinoblastoma protein (pRb).
The retinoblastoma gene (Rb) encodes a 928-amino acid phosphoprotein, which
arrests cells in the G1 phase (Weinberg 1995). pRb is sequentially phosphorylated
and dephosphorylated during the cell cycle. The hyperphosphorylated (inactive)
form predominates in proliferating cells, whereas the hypophosphorylated (active)
form is generally more abundant in quiescent or differentiating cells (Chen et al.
1989).
Being the first tumor suppressor identified, Rb was cloned as the cause of
a rare eye tumor (retinoblastoma) seen in children (Friend et al. 1986; Fung et al.
1987; Lee et al. 1987) Intensive studies about it showed that it is an important
actor in cellular regulation. Its tumor suppressor activity was demonstrated by
introduction of the wild type Rb into Rb-deficient tumor cells, which led to
blocking of malignant phenotypes (Huang et al. 1988). Most striking evidence
about its tumor suppressor activity was that mutations of Rb were not just seen in
retinoblastoma, but also in many other cancers such as osteosarcoma, small cell
lung cancer, prostate cancer, and breast cancer (Friend et al. 1986; Fung et al.
1987; Harbour et al. 1988; Lee et al. 1988; T'Ang et al. 1988; Bookstein et al.
41990). The children with hereditary retinoblastoma have 30-fold increased risk
of developing other kind of tumors in their lives (Eng et al. 1993; Moll et al.
1997).
In addition to mutations constitutive inactivation of pRb protein occurs by
hyperphosphorylation or by binding of some viral oncoproteins such as
adenovirus E1A, SV40 large tumor antigen, and human papillomavirus (HPV) E7
(Sherr 1996; DeCaprio et al. 1988; Whyte et al. 1988; Dyson et al. 1989).
1.1.1  STRUCTURE OF pRb
Domains A and B are the most important domains of pRb. These domains
are highly conserved among many species from human to plants, indicating their
importance. Two domains interact with each other forming a central pocket
(Chow and Dean 1996; Lee et al. 1998).  The identified germline retinoblastoma
mutations lead to the disruption of the pocket region (Qin et al. 1992, Horowitz et
al. 1990). Viral oncoproteins HPV-16 E7, adenovirus E1A, and SV-40 large T
antigen containing LXCXE motif, were shown to bind pRb at the pocket with
domain B in a domain A dependent manner (Whyte et al. 1988; Dyson et al. 1989;
Ludlow et al. 1989; Lee et al. 1998, Kim and Cho 1997). There are other
endogenous proteins binding to pRb having LXCXE-like sequence such as
histone deacetylase HDAC1, HDAC2, the ATPase, and BRG1 of the SWI/SNF
nucleosome remodeling complex (Dunaief et al. 1994; Brehm et al. 1998; Luo et
al. 1998; Magnaghi et al. 1998).
E2Fs, lacking the LXCXE motif, bind pRb at a distinct site involving
points of contact in both the pocket and in the C-terminal region (Huang et al.
1992; Lee et al. 1998).
Another region at the C-terminal of pRb is essential for binding of c-Abl
tyrosine kinase and MDM2. This site is distinct from the E2F site in the carboxy-
terminal region (Welch and Wang 1993; Xiao et al. 1995). pRb inhibits c-Abl
when bound and hyperphosphorylation of pRb releases c-Abl (Welch and Wang
1993; Whitaker et al. 1998).
5There is not yet clear information about the role of the interaction between
pRb and MDM2.  In addition to the data showing that MDM2 inhibits pRb, there
are also recent indications that pRb may be inhibiting the anti-apoptotic effects of
MDM2 by forming a trimeric complex with MDM2 and p53 (Hsieh et al. 1999).
The consensus phosphorylation sites of pRb, which are important for
regulation by CDKs, are mostly present in its amino-terminal region. There are
also several proteins known to be interacting with amino-terminal such as MCM7
(a replication licensing factor), a novel G2/M cycle-regulated kinase , and some
other proteins with unknown functions (Sterner et al. 1998; Sterner et al. 1995;
Durfee et al. 1994).
1.1.2      pRb IN REGULATION OF E2F TRANSCRIPTION FACTORS
 Interaction between E2Fs and pRb is the mostly studied part of pRb
function. At least two mechanisms were suggested for the repression of E2Fs by
pRb. First, binding of pRb to E2Fs, can block its activity to activate transcription
(Flemington et al. 1993; Helin et al. 1993). Second, the pRb may form a repressor
complex at promoters and can actively repress the transcription of E2Fs (Bremner
et al. 1995; Sellers et al. 1995; Weintraub et al. 1995). First mechanism involves
the physical block of E2F by pRb binding within the transactivation domain of
E2F. However second mechanism was proposed to be mediated by HDACs which
were recruited by pRb. HDACs recruited to the promoter region where pRb and
E2F are complexed, may block the access of transcription factors to the promoter
by remodeling the chromatin structure (Kingston and Narlikar 1999; Kornberg
and Lorch 1999; Wolffe and Hayes 1999). On the other hand E2F1 was shown to
interact with the histone acetyl transferases p300/CBP and p/CAF (Trouche et al.
1996). Acetylation of E2F1 increases its affinity to DNA (Martinez-Balbas et al.
2000). Recruitment of HDACs by pRb may have role in negation of the
acetyltransferase activity of the HATs recruited by E2F1 and acetylation of E2F1
(Harbour JW and Dean DJ, 2000).
Another class of chromatin remodeling complexes is the one dependent on
ATP hydrolysis and these complexes influence the binding of transcription
factors to the promoters by positioning the nucleosomes (Tyler and Kadonaga
61999; Schnitzler et al. 1998; Lorch et al. 1999). The human homologs of yeast
SWI2/SNF2 were characterized as BRG1 and BRM and they were found to be
interacting with pRb (Dunaief et al. 1994; Singh et al. 1995). Each multi-subunit
of SWI/SNF complexes contains an ATP-ase subunit. Several studies suggested
that these complexes might have role in transcriptional activation of some
promoters by recruiting some activators and HATs (Cosma et al. 1999; Tyler and
Kadonaga 1999). On the other hand it was also shown that mutant SWI2/SNF2
activated more genes than it repressed, which might be due to dual functions of
the complex as an activator or repressor (Holstege et al. 1998).
 Simultaneous binding of BRM and E2F proteins to pRb, provides another
possibility, in which a SWI/SNF-pRb-E2F complex can form on E2F binding sites
of promoters (Trouche et al. 1997). Over-expression of BRG1 in BRG1 and BRM
deficient cells caused cell cycle arrest in a pRb dependent manner. Furthermore
dominant negative forms of BRG1 and BRM blocked the growth suppression by
pRb (Dunaief et al. 1994; Strobeck et al. 2000). A recent document showed that
both HDAC and SWI/SNF complexes could be recruited to a single complex by
pRb.
Singh et al suggested a role for pRb in activation of transcription on some
glucocorticoid receptor promoters. It is possible that pRb-SWI/SNF complex
recruited to the glucocorticoid receptor where HAT activity is dominant, may be
responsible for the transactivation role (Singh et al. 1995). In a study MyoD was
shown to require pRb for transactivation and induce myogenic differentiation.
This effect was thought to be independent of E2Fs (Gu et al. 1993; Sellers et al.
1998).
HDAC independent mechanisms repressing transcription actively were
suggested for pRb, possibly involving co-repressors such as CtIP, RBP1, and
HBP1 (Luo et al. 1998; Meloni et al. 1999; Yee et al. 1998; Lai et al. 1999a). CtIP
inhibits CtBP which is an E1A binding protein (Schaeper et al. 1998). pRb pocket
domain was the binding region for CtIP. CtIP had an intrinsic repressor activity,
which required a motif mediating interaction with CtBP (Meloni et al. 1999).
RBP1 being another pocket binding protein, was shown to be an inhibitor of E2F
transactivation and suppressor of cell growth when exogenously expressed (Lai et
7al. 1999b). RBP1 is known to recruit HDAC with one of its two repression
domains and the HDAC-RBP1-pRb complex might be suppressing transactivation
at E2F promoters (Lai et al. 1999a).
1.1.3         REGULATION OF pRb BY PHOSPHORYLATION
Sixteen potential phosphorylation sites for pRb were identified. Such a
high number of sites provide the protein to oscillate between
hyperphosphorylated to hypophosphorylated and unphosphorylated states. Three
different kinase complexes were found to be phosphorylating pRb during cell
cycle in a sequential manner. Cyclin D-CDK4/6, cyclin E-CDK2 and cyclin A-
CDK2 phosphorylate pRb at early G1, near the end of G1 and during S-phase
respectively (Sherr et al 1996) (Figure 1). The high number of sites and their
phosphorylation status appear to have different consequences for the functions of
pRb. For instance, different sets of phosphorylations regulate binding of E2F,
LXCXE proteins and c-Abl to pRb (Knudsen and Wang 1996, 1997). First
phosphorylation by CDK4/6 makes pRb hypophosphorylated and active
(inhibiting E2F). Additional phosphorylation by CDK4/6 leads to
hyperphosphorylated and inactive form of pRb in later G1 (Ezhevsky et al. 1997).
For a successive phosphorylation both cyclin D-CDK4/6 and cyclin E-CDK2
complexes were found to be required (Lundberg and Weinberg 1998). A
mechanism suggested by Harbour et al states that cyclin D-CDK4/6 appears to
phosphorylate specific sites in the carboxy-terminal region of pRb. An intra-
molecular interaction between C-terminal region and a lysine patch, which is
positively charged around the LXCXE-binding site in domain B, is triggered.
HDAC is removed from the pocket as a result of this interaction. pRb is then
unable to repress cyclin E gene (CCNE). Cyclin E is expressed as a result of
disruption of pRb-HDAC complex by cyclin D-CDK4/6 (Harbour et al. 1999;
Zhang et al. 2000). Overexpressed cyclin E was shown to be enough to override
Rb-mediated G1 arrest (Zhang et al. 2000).
Interestingly phosphorylation of pRb by cyclin D-CDK4/6 was not only
shown to remove HDAC but also recruit cyclin E-CDK2 to the pocket (Adams et
al. 1999; Harbour et al. 1999). Cyclin E-CDK2 then facilitated phosphorylation of
Ser 567, which was buried within the domain A-domain B interface and not
8accessible before phosphorylation by cyclin D-CDK4/6 (Harbour et al. 1999).
Phosphorylation of Ser 567 caused release of E2F1 from the pRb. Further data
showed that Ser567 was the only phosphorylation site being the target of most
missense mutations naturally occurring in tumors (Templeton et al. 1991).   
1.1.4  OTHER POCKET PROTEINS
In addition to pRb there are two more pocket proteins identified
homologous to pRb, called p107 and p130. Actually the spacer region between
two domains A and B of pRb is not conserved in p107 and p130 or among
species. This region is only conserved between p107 and p130 and has a p21-like
sequence. Spacer region was found to be important for inhibition of the cyclin E-
cyclin A/CDK2 complexes, and growth suppression by P107 (Ewen et al. 1992;
Zhu et al. 1995b; Adams et al. 1996; Lacy and Whyte 1997). Both homologs were
able to bind viral oncogenes, inhibit E2F-responsive promoters, recruit HDAC,
actively repress transcription and arrest the growth of cells when over-expressed
as pRb (Zamanian and La 1993; Ferreira et al. 1998; Bremner et al. 1995;
Starostik et al. 1996; Zhu et al. 1993; Claudio et al. 1994). There were also
differences between pocket proteins and their target E2Fs during cell growth and
terminal differentiation. pRb was able to bind E2F1-E2F4, however p107 and
p130 were able to bind to E2F4 and E2F5. Furthermore it was found that during
quiescence and differentiation of muscle cells the abundant pocket protein-E2F
complex was the p130-E2F4 (Hijmans et al. 1995; Sardet et al. 1995; Nevins
1998). pRb-E2F complexes were replaced with p130-E2F complexes in myotubes
in order to maintain inhibition DNA synthesis (Corbeil et al. 1995; Kiess et al.
1995; Shin et al. 1995).  It was suggested by genetically modified animal
experiments that three pocket proteins had overlapping and distinct functions.
Retinal tumors were detected frequently in chimeric both Rb-/- and p107-/- mice
but not seen in chimeric Rb-/- mice. A parallel result was development of Rb-/-
mice normally, whereas homozygous loss of p107 in addition to Rb resulted in
growth retardation and early mortality (Robanus-Maandag et al. 199; Jacks et al.
1992; Lee et al. 1996). Homozygous deletion of p107 together with homozygous
loss of Rb resulted in lethality two day earlier than only homozygous Rb deletion
9did in mid-gestation (Clarke et al. 1992; Jacks et al. 1992; Lee et al. 1992; Lee et
al. 1996).
Arrest of cell growth by p16 was known to depend on only Rb, however
p16 failed to arrest MEFs which were Rb+/+, p107-/- , and p130-/-. This means in
addition to pRb, p107 and p130 are required for p16 mediated growth arrest.
Explanation of this situation might be the binding of p107 and p130 to cyclin
E/CDK2 and cyclin A/CDK2, and titrating CDK2 activity down to a level that
cell cycle arrest by pRb is efficiently done (Hannon et al. 1993; Zhu et al. 1995b)
1.1.5       E2F TRANSCRIPTION FACTORS
There are eight different transcription factors identified to have E2F
activity. Due to structural and functional differences made they are divided into
two groups as E2F s and DPs. (E2F1-E2F6) and (DP1 and DP2) are the members
of two groups respectively (Dyson et al 1998; Helin et al 1998). Any
combinations of E2F-DP hetero-dimers possible were identified in vivo (Bandara
et al 1993; Helin et al 1998; Krek et al 1993; Wu et al 1995; Trimarchi et al
1998). TTTCCCGC was the consensus sequence preferentially recognized by all
E2F-DP complexes.
 Different transcriptional responses to different E2F–DP dimers depend on
the identity of the E2F moiety and other proteins associated with the complex.
E2Fs are also divided into three in themselves; activators, repressors and E2F6
(being the last group and its only member).
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Figure 2: Structures of E2F family of proteins
1.1.5.1     The 'activating' E2Fs
These are the potent transcriptional activators and include the E2F1, E2F2
and E2F3. E2F1-DP complex is a potent activator of E2F-responsive promoters,
and E2F2 and E2F3 (highly homologous to E2F1) have similar transactivation
properties (Bandara et al 1993; Helin et al 1998; Krek et al 1993; Ivey-Hoyle et al
1993; Lees et al 1993) Activating E2Fs may have repressive effects on promoters
by recruiting pRb, but over-expression assays and mutant mouse models
suggested roles for them in activation of genes essential for cell proliferation and
apoptosis.
1.1.5.1.1 Triggering S-phase entry and apoptosis
 Any of the activator E2F triggers entry of quiescent cells into cell cycle,
with a DNA-binding and transactivation dependent manner when over-expressed
(Johnson et al 1993; Qin et al 1994; Lukas et al 1996). In some situations, they
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were able to overcome TGF-β, and CKI mediated growth arrest signals
(DeGregori et al 1995; Schwarz et al 1995; Mann et al 1995). Transformation of
some primary cells was also induced by activator E2Fs (Johnson et al 1995; Shan
et al 1994; Singh et al 1994; Xu et al 1995). Blocking of active E2F3 with E2F3
antibodies resulted in cell cycle arrest in primary cells. Moreover, in MEFs E2F3-
/- almost all E2F-responsive genes failed to be activated in response to mitogens
and the rate of proliferation of primary and transformed cells  decreased (Leone et
al 1998; Humbert et al 2000). Inactivation of all three E2Fs completely blocked
the cell proliferation, suggesting overlapping functions for three E2Fs in
proliferation.
On the other hand it was shown that deregulation of E2F1 was found to be
inducing apoptosis in both p53-dependent and independent ways (Dyson et al
1998). For p53 dependent manner, p19ARF was thought to be the mediator of the
effect. E2F1 was found to be transcriptionally activating p19ARF and p19ARF was
known to bind and block MDM2. The free and stabilized p53 then induced
apoptosis (DeFregori et al 1997; Bates et al 1998). Alternative p53-independent
pathways might be through transactivation of another p53 family or a non-
transcriptional mechanism involving TNFR-associated survival factors (Phillips
et al 1999; Irwin et al 2000; Lissy et al 2000; Stiewe et al 2000).  However there
are contradicting data about the potential of three activator E2Fs to induce
apoptosis. First group of data suggested that only E2F1 had apoptosis inducing
potential. It was shown that MEFs deficient of E2F1 were resistant to c-myc
induced apoptosis, but not the ones deficient of E2F2 or E2F3 (DeFregori et al
1997; Lissy et al 2000; Kowalik et al 1998; Leone et al 2001) . On the other hand
three of the E2Fs had the similar potential to activate apoptosis in another study.
Furthermore it was also shown that neither E2F1-/- nor E2F3-/- MEFs showed a
significant difference in apoptotic response than wild types did in response to
different apoptotic stimuli. (Vigo et al 1999)
1.1.5.1.2    Regulation of “activator E2Fs”
  There is a specific regulation of activating E2Fs by pRb but not by p107 or
p130 in normal cells (Lees et al 1993). Upon phosphorylation of pRb in late G1,
E2Fs were released and this release correlated with the activation of E2F-
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responsive genes. Both over-expression of E2Fs and the functional inactivation of
pRb induced the same phenotype in tumors and embryonic tissues (Mulligan et al
1998). Mutation of E2F1 or E2F3 suppressed all these phenotypes including
deregulated proliferation and apoptosis (Tsai et al 1998; Ziebold et al 2001).
1.1.5.1.3    Role in normal development
 Although activating E2Fs had similar effects on proliferation and
apoptosis, deficiency of E2F1 and E2F3 in mice showed completely different
developmental phenotypes. There was a high number of E2F3-/- mice died in
utero, and prematurely of congestive heart failure. On the other hand E2F
deficient mice were viable and fertile with a number of tissue-specific
abnormalities such as an excess of T cells, the development of testicular atrophy
between 9 and 12 months of age and development of many kinds of tumors
between 8 and 18 months of age (Jeffrey M. Trimarchi and Jacqueline A. Lees,
2002).
Recent studies showed that E2F1 was stabilized as a result of
phosphorylations by ATM and ATR. Chemotherapic agents also increased E2F1
protein levels. Further studies indicated that E2F1 might also be involved in the
DNA-damage-response pathway (Meng et al 1999, Lin et al 2001) NBS1 and
MRE Recombination/repair complex was shown to associate with E2F1 (Maser
RS et al 2001). These data suggest further roles for E2F1 and maybe for other
members of E2F family in DNA repair mechanisms.
The collaborative effects of E2F1 and E2F2 were shown by Zhu and
colleagues in the regulation of haematopoietic cell proliferation, differentiation
and tumor suppression (Zhu JW 2001). The developmental defects seen in
individual E2F1-/- or E2F3-/- mice deepened in mice defective of both E2F1 and
E2F3 (Wu, L. et al 2001) As a conclusion activator E2Fs seem to have
overlapping functions in proliferation, induction of apoptosis and development.
The important difference seems to be their tumor suppressive effects. It was
shown that E2F3 mutation did not result any increase in tumor formation alone or
together with E2F1 mutation, as a demonstration of tumor repressive effects of
only E2F1 and E2F2 but not E2F3 (Trimarchi & Lees 2002).
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1.1.5.2       The 'repressive' E2Fs
The two member of this group E2F4 and E2F5 were called ‘repressive
E2Fs’, because E2F-responsive genes were actively repressed by the pocket
proteins recruited by these E2Fs. They were found to be associate with both p107
and p130 (Dyson, N. et al 1993; Beijersbergen, R. L. et al 1994; Hijmans, E. M et
al 1995; Vairo, G et al 1995) Regulation of repressive E2Fs was shown to be
different from activating E2Fs. First of all, the cell cycle stages, at which these
factors were detected, differ from each other. Repressive E2Fs were mostly
detected at G0, but activating E2Fs were abundant in actively dividing cells
(Ikeda, M. A et al 1996; Moberg, K et al 1996) Second difference was the pocket
proteins they bound in vivo (Dyson et al 1993; Beijersbergen et al 1994; Hijmans
et al 1995; Vairo et al 1995; Ikeda et al 1996; Moberg et al 1996; Lees et al
1993). While pRb was the regulator of activating E2Fs, E2F5 was regulated by
p130 and E2F4 was regulated by both pRb and p130.  Third level of regulation
depends on the cellular localization of the E2Fs. An interesting structural
difference between activating and repressive E2Fs is the presence of a NLS
(nuclear localization signal) in activating E2Fs and a NES (nuclear export signal)
in repressive E2Fs. NLS caused activating E2Fs to be constitutively nuclear. On
the other hand repressive E2Fs were kept in the cytoplasm if not associated with
pocket proteins. Once they bound to a pocket protein they were taken into nucleus
with the pocket protein (Verona, R. et al1997; Iavarone, A et al 1999). This
means, in the absence of pocket proteins they are cytoplasmic and do not have
any transactivating property in vivo. When associated with pocket proteins they
are nuclear but still can not activate any promoter due to the repression by pocket
proteins and the chromatin remodeling factors recruited.
 In contrast to activating E2Fs, repressive E2F–DP–pocket-protein
complexes repressed E2F-responsive genes. It was seen that in G0 and early G1
phases of cell cycle, promoters were mostly occupied by E2F4, p107 and p130.
Additionally, mutations of the E2F-binding sites increased the amount of
transcripts from known E2F-responsive genes (Dalton, S et al 1992; Lam, E. W et
al 1993; Hsiao, K. M et al 1994; Takahashi, Y et al 2000; Wells, J. et al 2000). In
later stages the repressive E2F-pocket protein complexes were replaced by
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activating ones. Consequently, there seems to be a two-level regulation of E2F-
responsive genes by activating and repressive E2Fs; association/dissociation
dependent regulation and transcriptional activation dependent regulation.
1.1.5.3          E2F6
E2F6 is the only member of this group. It has repressive effects as the
repressive E2Fs. However there are other molecules regulating E2F6 function,
instead of pocket proteins and recruited chromatin remodeling complexes.
Binding of Ring1 and YY1 binding protein and Bmi-1 which are mammalian
Polycomb (PcG) complex components, was thought to be the mediators of E2F6
functions. The structural difference of E2F6 prevented its regulation by pocket
proteins, because it lacks all domains excluding DNA binding and dimerization
domains found in other E2Fs. Lacking the transactivation region, E2F6 repressed
E2F-responsive genes (Trimarchi, J. M. et al 1998; Cartwright, P et al 1998;
Gaubatz, S et al 1998).
1.1.6           E2F1-RESPONSIVE GENES
There are a pack of genes having E2F binding sites (Table 1). As
mentioned previously, repressive E2Fs mostly repress and activating E2Fs
activate transcription of these genes when overexpressed. Being an intensively
studied activating E2F, E2F1 was found to activate a variety of genes having
different functions such as induction of proliferation, DNA synthesis and
apoptosis. Such variety of genes suggests dual roles for E2F1 in regulation of cell
cycle. It was shown before that overexpression of E2F1 in different systems could
cause apoptosis or proliferation and transformation. Jeffrey M. Trimarchi and
Jacqueline A. Lees proposed a threshold model for dual functions of activating
E2Fs. The summary of this model is that there is a pool of active E2Fs in each
cell. When this pool of active E2Fs reaches a first threshold level it activates
proliferation. The second threshold level is later than the first one, and indicates
problems in the cell. When the pool of active E2Fs reaches second threshold, they
activate apoptotic genes. Seeming a good model, this scenario has not been
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proven yet. It is also questionable what prevents activation of apoptotic genes
before reaching the second threshold level.
It was shown that induction of apoptosis by E2F1 over-expression was
mediated by p14ARF, transcription of which was induced by E2F1. p14ARF protein
caused stabilization and accumulation of active p53 by inhibiting the MDM2.
Consequently p53 induced apoptosis.  However apoptosis was induced by E2F1
overexpression in p14ARF and p53 deficient systems, suggesting other apoptotic
mechanisms independent of p53. There are data suggesting another p53 family
member as a candidate for induction of p53 independent apoptosis. P73 was
shown to be directly transactivated by E2F1, and induced apoptosis in p53
deficient cell lines (Stiewe & Putzer 2000; Irwin et al 2000). Induction of
apoptosis in T-cells by TCR activation was shown to be mediated by the p73
which was upregulated by E2F1 (Lissy et al 2000).
Table 1: The genes identified to have putative
             E2F1 binding sites on their promoters (*)16
                
Gen
e name
Direct/
Indirect
Induction Function Description R
ef
er
en
ce
     
Thymidine
Kinase n.d Replication  **
Thymidylate
synthetase n.d Replication  **
ORC1 n.d Replication  **
ORC6 n.d Replication  **
cyclin A n.d Cell Cycle regulation  Ψ
CDC2 n.d Cell Cycle regulation  Ψ
CDC25A n.d Cell Cycle regulation  Ψ
P107 n.d Cell Cycle regulation
Retinoblastoma gene
homolog
Ψ
Rb n.d Cell Cycle regulation Retinoblastoma gene Ψ
c-myc n.d Cell Cycle regulation  Ψ
N-myc n.d Cell Cycle regulation  Ψ
E2F1 n.d Cell Cycle regulation
Activating E2F family
member 1
Ψ
E2F2 n.d Cell Cycle regulation
Activating E2F family
member 2
P14ARF Direct Apoptosis  ¥
TP73 Direct
apoptosis,
development Tumor protein p73 §
B-Myb n.d    
DHFR n.d cell cycle Dihydro Folate Reductase  
DNA
polymerase
alpha n.d cell cycle   
Cdc6 n.d Cell Cycle control
Limiting component of pre-
replication complex ¶
CCND1 Direct Cell Cycle control cyclin D1
§
CCNE1 Direct cell cycle control cyclin E1 §
CCNE2 Direct cell cycle control cyclin E2 §
Map3K5 n.d Others
Mitogen activated protein
kinase kinase kinase 5
§
CD9 Indirect Others CD9 antigen (p24) §
ENO2 n.d Others enolase2(neuronal) §
IFNA2 n.d Others Interferon alpha2 §
KIAA0455 Indirect Others KIAA0455 gene product §
KIAA0767 Direct Others KIAA0767 gene product §
SERPINF2 n.d Others
Serine (or cysteine)
proteinase inhibitor, clade F
(alpha-antiplasmin, pigment
epithelium derived factor),
member 2
§
UNG2 n.d Others Uracil-DNA glycolase 2 §
FGF-2 n.d Cancer related Fibroblast growth factor 2 §
FGFR3 n.d Cancer related
Fibroblast growth factor
receptor 3
§
MMP16 Indirect Cancer related matrix metalloproteinase 16 §
17
TP53BP2 n.d Cancer related
tumor protein p53-binding
protein
§
VEGF-B Indirect Cancer related
Vascular endothelial growth
factor
§
BAD n.d Apoptosis
BCL2-antagonist of cell
death
§
BAK1 n.d Apoptosis BCL2-antagonist /killer 1 §
BIF n.d Apoptosis
BH3 interacting domain
death agonist
§
CFLAR (FLIP) n.d Apoptosis
CASP8 and FADD-like
apoptosis regulator
§
MAP3K14 Direct Apoptosis
Mitogen activated protein
kinase kinase kinase 14
§
ARHGAP4 Indirect
Cell Cycle
control/DNA
replication/
centrosome
duplication
Rho GTPase activating
Protein
§
RAD52 Direct DNA replication
RAD52 (S.cerevisiae)
homolog
§
RFC3 Indirect DNA replication
replication factor C
(activator 1) 3
§
STK15 Indirect
Cell Cycle
control/DNA
replication/
centrosome
duplication serine threonine kinase 15
§
TNSF9 n.d
Cell Cycle
control/DNA
replication/
centrosome
duplication
Tumor Necrosis factor
superfamily, member 9
§
TRA1 Indirect
Cell Cycle
control/DNA
replication/
centrosome
duplication
tumor rejection antigen
(gp96) 1
§
* )Some of these genes were shown to be direct and indirect targets of E2F1. Some of them are not yet shown to be
activated by E2F1 experimentally.
**) Helin et al 1998
Ψ ) Slansky et al 1996
§ ) Stanelle et al. 2002
¥ ) DEGregori  et al 1997; Bates  et al 1998
¶) Dyson  et al 1998
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1.2     p53 FAMILY OF PROTEINS
p53 is a tumor-suppressor protein, which was found to be inactivated in
50% of human cancers studied, as a result of mostly missense point mutations.
There were also cases in which p53 was functionally inactivated by some viral
oncogenes. It was activated by oncogenic activation of DNA damage. Post
translational modification of p53 as a result of such stimuli stabilizes the protein
and cause structural modifications on p53 , which allows it to oligomerize, bind
to DNA and activate its target genes including p21(CIP) and Bax controlling cell
cycle and apoptosis respectively (Giaccia and Kastan 1998). These modifications
are phosphorylation and acetylation of the protein mainly at amino-terminal
regions and carboxy-terminal regions respectively.
Activation of p53 is under a strict regulation due to its lethal effects on the
cell. In normal cells its half-life is very short and its degradation is under the
control of ubiquitin ligase MDM2, which targets p53 to ubiquitin dependent
proteolysis. MDM is constitutively bound to p53 in its unphosphorylated state.
Phosphorylation of N-terminal residues of p53 causes release of p53 from
MDM2. Free p53 which is stabilized and activated transactivates its target genes,
which induce either cell cycle arrest or differentiation or apoptosis. Being a
critical protein for cell life p53 is an inducer of its own assassin MDM2. The
levels of p53 in the cell is balanced by expression of MDM2 transactivated by
p53 itself.
Being a very complex formation, life again put another guard over the
MDM2. One of the most interesting loci identified is the multiple tumor
suppressor locus (MTSL), encoding two different proteins, both of which are
found to be anti-proliferative, and using alternative promoters. p16INK4A and
p14ARF are these two protein products (Serrano M. 2000).  p14ARF was identified
as an inhibitor of MDM2, so over-expression of p14ARF resulted in p53
stabilization and activation of p53 target genes. As expected, p14ARF deficient
mice developed tumors similar to p53 deficient mice did. There are several
factors controlling p14ARF transactivation, one of which is the E2F1. This
proposes a model for oncogenic activation of p53 as summarized below:
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Figure 3: Dual roles of E2F1 in activation of cell progression and activation of
p53
1.2.1       p73
Until 1997, it was thought that there was not any homolog of p53 gene.
Kagdad and his colleagues identified the first sibling of p53 in a hybridization
screen of COS cell line (Kaghad et. al 1997). Gene was localized to small arm of
chromosome 1, deletion of which was common in different tumor types such as
neuroblastoma (Kagdad et al 1997), for lung (Nomoto et al. 1998), for non-
astrocytic brain tumors (Alonso et al. 2001), and for HCC (Mihara et al. 1999),
suggesting a tumor suppressor role for the new p53 homolog, p73.
p73 has high homology with functional domains present in p53 protein
(Kagdad et al 1997). There are 60%, 38%, and 29% homologies in DNA binding,
oligomerization and transactivation domains respectively, between p53 and p73
proteins. The DNA binding domain of p73 is not a target of mutations in tumors
as its homolog in p53 (Kagdad et al 1997). High homology between p73 and p53
suggests similar functions for two proteins. C-terminal extension of p73, which is
not present in p53, contains two domains called SAM and PS domains. SAM
domain (Sterile Alpha Motif) is a putative protein-protein interaction region,
found in many signaling proteins involved in developmental processes.  Presence
of this domain suggests roles for p73 in development.
pRb E2F1 Cyclin E Cell cycle progression
p14ARF
MDM2 p53
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Figure 4: Homology of p53 and p73
A distinct property of p73 gene from p53 gene is the presence of several N-
terminal and C-terminal splice variants of p73 which are not present in p53. At
least six types of C-terminal variants and at least three N-terminal variants are
present (Figure 5) (Kaghad et al. 1997; Zaika et al. 1999). In normal tissues the
p73α and P73β variants are abundant. It was shown that tumorigenesis led in
these tissues accumulation of different transcripts. P73β was shown to have a
potential of transactivation as much as p53 had. Following potential order was
 p73γ, p73α and p73ε. The other three forms (α, γ, ε) interestingly showed to
endogenous p53 activity (Ueda et al. 1999). Different p73 forms could
oligomerize together. This inter-association may result in different responses
depending on the components of the oligomer. The N-terminal variants lacking
transactivation domain and C-terminal variants having less transactivation ability
may act as inhibiting factors for other variants in hetero-oligomers, as dominant
negative forms. Actually such data were presented by Ueda et al showing that the
p73 (p73γ, ε) isoforms decreased the transactivation potential of p53, p73α and
p73β (Ueda et al).  In another study it was shown that the expression of an N-
terminal splice variant identified by Kaghad M. called Delta-exon2 was increased
in breast cancer cell lines (Fillipovich et al. 2001) and in vulval cancers (O’Nions
et al. 2001; Kaghad M et al 1997. DN-p53 transcript is initiated from an
alternative in frame methionine in exon 3. It lacks the first 48 amino terminal
amino acids, which are essential for transactivation. Conserving the DNA-binding
and oligomerization domains, this form may oligomerize with other forms and
bind to DNA.
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Figure 5: Organization of exons in different splice variants of p73 gene (A) and
structural domains and comparison of different splice variants of p73 proteins (B)
Similar stimuli activating p53 could activate p73. Especially genotoxic
stress, activated p73 in a c-Abl dependent manner, in which p73 was stabilized as
a result of phosphorylation by c-Abl (Agami et al. 1999, Gong et al. 1999, Yuan
et al. 1999).  However there were differences in genotoxic agents activating p53
and p73. Cis-platin and ionizing radiation were the two agents activating p73 like
p53. Activated p73 transactivated similar genes, those were activated by p53 such
as Bax, p21, PIG series of genes, 14-3-3σ, a ribonucleotide reductase enzyme
subunit and p57KIP2 , which are important actors in cell cycle regulation, DNA
damage sensing, repair, and apoptosis (Stiewe and Putzer 2002).
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Figure 6: Signals Activating p73 and p53  
 Posttranslational regulation of p73 was shown to be done also by MDM2
and its related protein MDMX (Ongkeko et al. 1999, Balint et al. 1999). The
amino acid residues of p53 for MDM2 binding are conserved in p73, however
binding of MDM2 and MDMX did not target p73 to degradation as MDM2 did
p53. p73 was stabilized as a result of MDM2 and MDMX binding. This
stabilization under the arms of MDMs did not increase but reduced the
transactivation capacity of p73 (Zeng et al. 1999; Balint et al. 1999, Dobbelstein
et al. 1999).
The C-terminal region which contain SAM domain and is not present in
p53 suggests different functions for p73 in developmental processes. In a study
with p73 knockout mice, it was shown that deficiency in p73 gene caused several
developmental defects such as hydrocephalus, hippocampal dysgenesis and some
secondary effects in pheromone sensory pathway, suggesting important roles for
p73 in neurogenesis. Interestingly this study, in which the spontaneous tumor
formation was not seen in p73 deficient mice, weakened the idea that p73 was a
tumor-suppressor (Yang et al. 2000).  Knock out studies provided discovery of an
alternative promoter within the intron 3 of p73 gene encoding a p73 transcript
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lacking the first three exons of p73 gene. This new form was named ‘Dominant
Negative’ form due to the absence of transactivation domain found in full length
p73. A similar form was identified for p63 the other member of the family.
Further studies showed that the mRNA levels of DN-p73 were higher in
developing and adult mouse tissues (Yang et al. 2000). Full length p73 was called
Transactivating p73 (TA-p73) due to presence of p53-like transactivation domain
at N-terminal region of the protein.
1.2.1.1   MUTATIONAL ANALYSIS OF p73
   Being a homolog of p53, p73 was thought to be a tumor suppressor. However,
screening of a legion of samples from different tumors revealed that just 0.5% of
them had p73 mutations. This number is 100 times less than p53, which was
mutated in 50% of tumors analyzed. P73 is thought to be deregulated at
epigenetic levels in cancers. In many studies it was shown that p73 was
expressed monoallelicaly or biallelically depending on the cell type, tissue, and
person, but all these data were contradictory to each other (Stiewe and Putzer,
2002). There has not yet been found any correlation between the allelic
expression of p73 and tumorigenesis.
 In several cancers such as neuroblastomas, lung cancers, astrocytic and
non-astrocytic brain tumors and hepatocellular carcinomas LOH incidence at
1p36 was reported to be quite high (Table 2).
A total of 11 polymorphisms were defined recurrently in different types of
cancers (Table 3). Although 11 different polymorphisms of p73 were identified
only two of them were shown to be associated with tumor progression. (Ryan et
al.2001), It was proposed in this study that change in the stem like secondary
structures in p73 mRNA as a result of different polymorphisms might affect
translational efficiency of the p73 mRNA.
The number of mutations detected up to now is just 15. Being most of
them point mutations causing amino acid substitutions, 3 deletions were also
identified. Interestingly two of these deletions do not affect the reading frame.
The hotspots (codons 175, 248, 249, etc) in p53 were interestingly not targeted by
p73 mutations.
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Table 2 : Summary of the studies defining the LOH at 1p36, mutation of p73 gene, polymorphisms of p73 gene and the expression of p73
RNA or protein (if otherwise is not indicated, it is RNA).
The bold lines are the references that we could obtain. The data for others are gathered from abstracts and the articles that cite them.
NT: Not Tested, T: tumor, N: Normal, +: positive, +/-: slightly positive, -: negative, prot: protein
Ref. Samples Number LOH Mutation Polymorp. Expression
Kaghad etal. 1997 various 17 NT 1(neurolastoma) 2 NT
Nomoto et al. 1998 lung ca. 62 42%(11/26) none 6 NT
Takahashi et al. 1998 prostatic ca. 106 6% none found T>N (α>β)
Mai  et al. 1998 (a) lung ca. 21 NT none 6 T>N
Sunahara et al. 1998 colorectal ca. 82 17%(8/46) none 3 T>N
Mai et al. (b) 1998 oligodendrioma 20 NT none found
Nimura et al. 1998 esophageal ca. 48 8% none found T=+(α>β)
Kovalev et al. 1998 neuroblastoma 42 NT none 4
Tsao et al. 1999 melanoma 24 NT none 9 NT
Kroiss et al. 1998 melanoma 17 NT none
Ichimiya et al. 1999 neuroblastoma 151 19% 2 4 T=+/-(α>β)
Yokomizo et al. (a) 1999 bladder ca. 30 NT none 6 T>N (α, β)
Han et al. 1999 various 185 NT 1(breast) 4 NT
Yokomizo et al. (b) 1999 prostate 31 NT none T=N
Yoshikawa et al. 1999 various 54 NT 3(lung) 5
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Herbst et al. 1999 melanoma 56 6%(/17) NT NT
Shishikura et al. 1999 breast 87 13% none T=N
Chi et al. 1999 bladder 45 NT none found T>N(x1-x3)
Zaika et al. 1999 breast 8 NT none 2 T>N(x2-x5)
Stirewalt et al. 1999 leukemia 60 none found
Schittek et al. 1999 melanoma 68 20% none NT T>N
Mihara et al. 1999 HCC 48 20% none 4 T=N(α>β)
Corn et al. 1999 leukemia/lymphoma35 NT none 4 T<N(x1-x3)
Kawano et al. 1999 leukemia/lymphoma115 NT none 2
Yokozaki et al. 1999 gastric adenoca 95 38% none found NT
Liu et al. 2000 neuroblastoma 31 NT none found
Schwartz et al. 1999 breast 77 NT none NT
Van Gele et al. 2000 Merkel cell ca. 15 NT 1  4 NT
Cai et al. 2000 esophageal  15 64% none 1 T>N
Ng et al. 2000 ovarian 70 50%(5/10) none NT T>N(prot)
Kang et al. 2000 gastric adenoca. 80 - none NT T>N
Peng et al. 2000 HCC 22 18% 1(5bp del)
Kong et al. 2000 neuroblastoma 50 38% none NT
Tsujimoto et al. 2000 oligodendroglioma 10 NT none found
Dominguez et al. 2000 breast 193 27% NT NT
Ahomadegbe et al. 2000 breast 59 32% none found T>N
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Fukushima et al. 2001 HCC            36 none
Shan et al. 2001 Parathyroid adenoma 32 37% none
El-Naggar et al. 2001 oral/laryngeal ca.     67 30-40 2 1 N=T(prot)
Nozaki et al. 2001 meningioma 27 NT none T>N
Alonso et al. 2001 non-astrocytic 65 50% 1 3
Ichimiya et al. 2001 neuroblastoma 272 28/151 2 (1 germline) ND
Barrois et al. 2001 neuroblastoma 61 7/20 NT NT
Alonso et al. 2001 astrocytic 60 20% none 5
Dominguez et al. 2001 breast 70 17% NT NT T>N
Lomas et al. 2001 meningioma 30 NT 1 NT NT
F-Laurens et al. 2001 HNSCC 17 NT none 1 N=T
Peters et al 2001 fam. prostate-brain 49 NT none found
Momoi et al.2001 cholangiocarcinoma 23 high
Ryan et  al. 2001 oesoophageal 84 14/37
Araki et al. 2002 squamus 41 73% none
Weber et al. 2002 HNSCC 68 ND none
Dong et al. 2002 Oligodendroglioma 44 NT 1 5 T<N
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Table 3: The summary of all identified mutations and polymorphisms of the p73 gene with references.
5’UTR-ATG :  A/G at nt 4 of ex 2 : Kaghad et al. 1997, Nomoto et al. 1998, Mai et al. 1998 (a), Tsao et al. 1999, Yokomizo et al.
(a) 1999
T/C at nt 14 of ex 2 : Kaghad et al. 1997, Nomoto et al. 1998, Mai et al. 1998 (a), Tsao et al. 1999, Yokomizo et al.
(a) 1999
Codons 101-200: S110L : Van Gele et al. 2000
173(ACT/ACC) : Mai et al. 1998 (a), Tsao et al. 1999, Yoshikawa et al. 1999, Cai et al. 2000, Lomas et al. 2001
146(CCG/CCA) : Alonso et al.  2001 (a), Lomas et al. 2001
Codons 201-300: R269Q : Han et al. 1999
245(GTG/GTA) : Yoshikawa et al. 1999, Zaika et al. 1999, Corn et al. 1999
G264W : Yoshikawa et al. 1999
Q291K : Alonso et al.  2001 (a)
204(AAC/AAT) : Alonso et al.  2001 (a), Lomas et al. 2001, F-Laurens et al. 2001
N204S : Lomas et al. 2001
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Codons 301-400 : 336(GCC/GCT) : Nomoto et al. 1998, Mai et al. 1998 (a), Nimura et al. 1998, Tsao et al. 1999, Mihara et al.
1999, Ichimiya et al. 1999, Yokomizo et al. (a) 1999, Yoshikawa et al. 1999, Kawano et al. 1999, Van Gele et al.
2000, Lomas et al. 2001
349(CAT/CAC) : Nomoto et al. 1998, Mai et al. 1998 (a), Nimura et al. 1998, Tsao et al. 1999, Mihara et al.
1999, Ichimiyaa et al. 1999, Yokomizo et al. (a) 1999, Yoshikawa et al. 1999, Corn et al. 1999, Kawano et al. 1999,
Van Gele et al. 2000, El-Naggar et al. 2001, Lomas et al. 2001
Codons 4010500: P405R : Ichimiya et al. 1999, Zaika et al. 1999
P425L : Ichimiya et al. 1999
Del 2 and 4 bp in coding exon 10 affecting codons 417-420 : Yoshikawa et al. 1999
S469R : El-Naggar et al. 2001
A472T : Kaghad et al. 1997
S477W : El-Naggar et al. 2001
Codons 501-636 : 557(GCG/GCA) : Nomoto et al. 1998, Nimura et al. 1998, Tsao et al. 1999, Mihara et al. 1999, Ichimiya et al.
1999, Yoshikawa et al. 1999, Corn et al. 1999, Van Gele et al. 2000
563(TCT/TCC) : Yoshikawa et al. 1999
610(GCG/GCA) : Nomoto et al. 1998, Mai et al. 1998 (a), Nimura et al. 1998, Tsao et al. 1999, Mihara et al.
1999, Ichimiya et al. 1999, Yokomizo et al. (a) 1999, Yoshikawa et al. 1999, Corn et al. 1999, Van Gele et al. 2000    
Del 12 bp at coding exon 13, so deletion of codons 604-606 : Yoshikawa et al. 1999
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1.2.1.2 Transactivating p73 (TA-p73)
The p73 locus seems to encode mainly two classes of proteins, with regard
to presence of transactivation domain at N-terminal or not. The first class
includes the TA-p53 and its C-terminal variants. The second group includes the
DN-p73, ∆exon2, ∆exon2-3 spliced forms and their C-terminal variants.
 Endogenous expression of TA-p73 and its C-terminal variants showed
p53 like properties. Oligomerization, binding to p53 response elements, and
transactivation of several genes having role in cell cycle regulation and apoptosis
(such as p21, 14-3-3-σ, PIG series (PIG3, PIG6, PIG7 and PIG11), MDM2, a
ribonucleotide reductase p53R2) are the p53-like biological activities of TA-p73
(Zhu et al 1998; Nakano et al. 2000).
The probable pro-apoptotic and cell cycle regulatory role of TA-p73 is cell
type dependent. TA-p73, like some other cell cycle regulatory proteins also
regulates the differentiation state of different cell types.
Activation of TA-p73 may cause different responses depending on the cell
type. Retinoic acid treatment with over-expression of TA-p73 of neuroblastoma
cell line, induced morphological and biochemical markers of neuronal
differentiation (De-Laurenzi et al. 2000) whereas neither p53 nor DN-forms of
p73 could cause any change in differentiation status of cells.  In EJ bladder
carcinoma cells TA-p73α and TA-p73β caused irreversible growth arrest together
with the markers of replicative senescence when over-expressed. The effects of
TA-p73α and TA-p73β were quite similar of neuroblastoma over-expression in
bladder cells (Fang et al. 1999).
1.2.1.3 Dominant negative p73 (DN-p73)
Transactivation domain of TA-p73, which has role in induction of cell
cycle arrest and apoptosis is absent in DN-p73. The proposed role for DN-p73 is
being the antagonist of TA-p73, its C-terminal isoforms and maybe p53. TP73
has an interesting gene architecture, in which two groups of proteins are encoded,
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one seem to be antagonist (one is probably oncogenic and the other is tumor
suppressive) of the other with the regulation under distinct promoters.
There is not quite much information about the function of DN-p73.
Withdrawal of Nerve Growth Factor (NGF) induced a p53 dependent apoptosis in
sympathetic neurons. In sympathetic neurons, when NGF (Nerve growth factor)
was withdrawn, apoptosis was induced in a p53 dependent manner. The protein
levels of DN-p73 were decreased suggesting a balance between p53 and DN-p73
on apoptosis. This idea was strengthened by the rescue of these cells from
apoptosis with adenoviral transfection of DN-p73 after NGF withdrawal (Pozniak
et al. 2000). Similarly infection of neuronal cells with both p53 and DN-p73
together did not lead these cells to go apoptosis. Pull down assays showed that
these two proteins form complexes in vivo, supporting their antagonist activity
(Pozniak et al. 2000).
1.2.2  INHIBITION OF p73 BY p53 MUTANTS
There are several oncogenic stimuli leading to upregulation of p53 and
TA-p73 such as E2F1 upregulation (as a consequence of Rb Pathway
dysregulations including, Rb mutation, pRb degradation, p16 gene mutations and
promoter methylations). Upregulation of TA-p73 in response to E2F1 or
stabilization of TA-p73 by c-Abl and over-expression induced apoptosis in cells
(Stiewe et al. 2000, Jost et al. 1997, Gong et al. 1999). As expected it was seen
that as a consequence of tumorigenesis the levels of TA-p73 was increased in
many tumors except leukemias and lymphomas. Although it is not very favorable,
it is very common that TA-p73 expression is prolonged in cancer cells. It was
found that some mutant forms of p53 could inhibit the probable apoptotic effect
of TA-p73 by direct protein-protein interaction. The cancer cells might generate
transactivation defective oligomers of TA-p73 and mutant p53, which can not
activate apoptotic genes. Direct interaction of TA-p73α and two mutant forms of
p53 (R175H and R248W mutants) was shown in a co-transfection experiment
with co-immunoprecipitation (Di Como et al. 1999). In the same study activity of
TA-p73 was shown to be decreased with p53 mutants. The interaction between
the mutant p53 and TA-p73 was not mediated by oligomerization domains but
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with a peptide motif in DNA binding domain, with the oligomerization domain
(Davison et al. 1999; Strano et al. 2000, Gaiddon et al. 2001).
1.2.3 ONCOGENIC ACTIVATION OF p73
The upstream pathways inducing p73 activation may give clues about the
role of p73. One of the striking discoveries about regulation of p73 was the
induction of p73 gene in transcriptional level by over-expression of some
oncogenes. Two Nature and a Nature genetics papers, showed that the induction
of p73 in response to E2F1 activation caused apoptosis. Lissy et al showed that
the TCR-AICD (T-cell receptor activation induced cell death) which had been
shown to be independent of p53, was mediated by the activation of p73, in
response to activation of E2F1 transcription factor (Lissy NA et al 2000). The
second paper in the same issue of Nature by Irwin et al was about the
transcriptional activation of p73 in response to over-expression of E2F1. E2F1
was shown to increase both mRNA and protein levels of p73 with northern blot
and western blot analysis respectively. P73 promoter was shown to be E2F1
responsive with reporter assays. Interestingly it was shown that different
members of E2F1 family had different dose dependent affinities on p73 promoter.
E2F1 and E2F4 were shown to be the most and less potent activators of the p73
promoter respectively. The physiological regulation of E2F1 during cell cycle
also correlated with the amount of p73 transcripts at different periods of cell
cycle in a starvation-refeeding experiment. A dominant negative form of p73
p73DD, was shown to decrease apoptosis in Saos-2 cells (p53 deficient)
transfected with E2F1, suggesting p73 as the mediator in the E2F1 induced
apoptosis. The last experiment with MEFs showed that, the p53-/- or p73 -/-
MEFs had a significant decrease in percentage of apoptosis (from 80% to 15%) in
response to E2F1 transfection. Thorsten Stiewe and Brigitte M. Putzer used
another approach to show the effect of E2F1 on p73 transcription and induction
of apoptosis. The increase in the RNA and protein levels were shown by semi-
quantitative RT-PCR and western blots respectively. A tumor derived p53
mutant, which directly inhibits p73 and interferes with its transactivation
function, was shown to reduce E2F1 mediated apoptosis.  “These results suggest
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that deregulated E2F1 activity might constitute a p53-independent, anti-
tumorigenic safeguard mechanism” (Stiewe T, & Putzer B 2000)
Additional oncogenes such as c-myc and E1A were shown to induce
transcription of p73. It was shown that in p53 deficient tumor cells, the
endogenous levels of p73α and p73β were shown to be induced in response to
E2F1, c-myc and E1A over-expression. Using p73 responsive reporter activity
and known endogenous p73 target genes, increase in the levels of p73
transcription activity was shown with again over-expression of oncogenes. As
E2F1, c-myc and E1A were shown to induce apoptosis. Apoptotic effect of these
oncogenes was demonstrated to be mediated by p73, using dominant negative p73
protein, which decreased apoptosis level in E1A or c-myc transfected Saos-2 cells
(Zaika A. et al 2001)
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1.3 AIM OF THE STUDY AND STRATEGY
Having putative opposing roles, TA- and DN- forms of p73 encoded in the
same gene with distinct promoters makes p73 gene an interesting target for
tumorigenesis studies. TA-p73 which was expected to induce apoptosis was
somehow ineffective in cancer cells, although its expression was elevated in
response to different stimuli including oncogenic activation. In a previous study
Sayan et al showed that in normal liver tissue the dominant negative form was
expressed but TA-p73 was not. However in 14/15 of cell lines and 3/7 tumor
samples of HCC, an acquired expression of TA-p73 was detected with semi-
quantitative RT-PCR. It was thought that this acquired expression might be a
consequence of E2F1 activation due to pRb pathway dysregulations. It was shown
with p14 and p16 semi-quantitative PCRs and western blotting for pRb that in
most of the samples pRb pathway seemed to be dysregulated, correlating with the
TA-p73 activation. On the other hand p53 of most cells were found to have
missense mutations or loss of expression. The mutant forms of p53 and DN-p73
expressed in these cells could be factors neutralizing apoptotic effects of acquired
TA-p73 expression.
It was also shown that E2F1 induced p53-independent apoptosis using TA-
p73 as a mediator in different cell types. However it is still not clear why and how
acquired expression of TA-p73 is favored without induction of apoptosis in
cancer cells. In the studies linking E2F1 and p73 to apoptosis it was shown that
only TA-forms of the p73 were activated. However it has not yet been shown
whether DN-form or other transactivation domain lacking forms (p73-∆exon2 and
p73-∆exon2-3) are the targets of E2F1. Such a dual role could be an
advantageous way for cancer cells to overcome apoptotic effects of active TA-
p73. E2F1 dependent activation of different splice variants of p73 may also be
cell type specific and in different cell types E2F1 over-expression may give
different responses. In order to show which forms of p73 are activated in response
to E2F1 over-expression we selected different cell lines having different
background of p53, pRb, p14, p16, and p73 status. With semi-quantitative RT-
PCR, changes in the expression levels of different forms were detected. E2F4
transfected and untransfected cells were used as negative controls. Later on, time-
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course activations of TA-p73 and DN-p73 forms were demonstrated using semi-
quantitative RT-PCR. This time just Cama-1 cell line was used. Cama-1 was a
good candidate because neither DN-p73 nor TA-p73 forms seemed to be
expressed in untransfected cells and a time course activation of p73 could be
demonstrated quite well in such a system. It may be important in what sequence
different forms are activated in determining the cell fate during tumorigenesis.
35
CHAPTER 2
MATERIAL
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2.1   COMMERCIAL KITS
QIAGEN Maxi-Prep Kit
MN’s Nucleospin Mini-Prep Kit
MN’s Nucleobond RNA isolation Kit
MBI’s RevertAid cDNA Synthesis Kit
MBI’s Recombinant Taq Polymerase PCR kit
ECL+ Immunodetection Substrate Kit
Promega’s pGEM-T TA-cloning Kit
2.2 BACTERIAL STRAINS
Strain Genotype Usage Reference
DH5α supE44 ∆lacU169
(φ80lacZ∆Μ15) hsdR17 recA1
endA1 gyrA96 thi-1 relA1
Host for
plasmid DNA
Hanahan
(1983)
2.3   PLASMIDS AND CONSTRUCTS
pCDNA3- TAp73     TA-p73 is cloned into pCDNA3 vector from cDNA
                                 (Kindly provided by T. Soussi, France).
pRC/CMV- E2F1      E2F1 is cloned into pRC/CMV vector from cDNA
 (Kindly provided by R. Bernards, Netherlands)
pRC/CMV- E2F4      E2F4 is cloned into pRC/CMV vector from cDNA
 (Kindly provided by R. Bernards, Netherlands)
pRC/CMV-p53          Wild Type p53 is cloned into pRC/CMV vector from cDNA
 (Kindly provided by T. Frebourg, France)
pEGFP-N2                 Encodes GFP protein (Clontech)
pGEM-T                   TA-cloning vector for sequence analysis (Promega)
(For extra information look at the Appendix)
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2.4    SOLUTIONS AND BUFFERS
LB medium
Tryptone                              10 gr
Yeast Extract                         5 gr
NaCl                                     10 gr
Agar                                      20 gr ( For Plates only)
Complete volume to 1 L with dd H2O, and autoclaved
SOB Medium
Per Liter;
2% Tryptone
0.5% Yeast extract          Autoclaved
10mM NaCl
2.5mM KCl
Then 20 mM MgSO4 and 10mmM MgCl2 are added.
SOC Medium
SOB+20mM Glucose (from filter sterilized 1M stock solution in ddH2O)
Ampicilline
Working Solution: 100µg/ml
Stock solution:     100 mg/ml
Kanamycine
Working solution: 25µg/ml
Stock solution     : 25 mg/ml
EDTA 0.5 M (pH:8.0)
For 1L
186.1 g EDTA is dissolved in 800 ml ddH2O.
pH is adjusted to 8.0 and volume is completed to 1L with ddH2O.
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Solution I
50 mM glucose
25 mM Tris.Cl (pH 8.0)
10 mM EDTA (pH 8.0)
Solution II
  0.2M NaOH (freshly diluted from 1 M stock)
 1% SDS
Solution III
5 M potassium acetate          60 ml
Glacial acetic acid             11.5 ml
H2O                                  28.5 ml
TE buffer pH 7.4
10mM Tris.Cl  (pH 7.4)
1mM EDTA (pH 8.0)
Buffer TB, for supercompetent cell preparation
10 mM PIPES
55mM MnCl2
15 mM CaCl2
250 mM KCl
pH 6.7
Filter Sterilized
Growth Medium for Mammalian Cells
500 ml DMEM
50 ml FBS
5 ml 100X Non-Essential amino acid mix
5 ml 100X Penicilline/Strpetomycine ((10000 units/ 10000μg)/ ml)
All are sterile.
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10 X PBS (Phosphate Buffered Saline)
80 g NaCl
2 g KCl
11.5 g Na2HPO4
2.4 g KH2PO4
Volume is adjusted to 1 Lt with ddH2O
1X PBS Buffer
10X PBS is diluted in 9 volumes of ddH2O and pH is adjusted to 7.3-7.6.
CaCl2    2.5 M             (stored at -20°C)
CaCl2       50mM           (stored at +4°C)
2 X BES Buffer
50 m BES
280mM NaCl
1.5 mM Na2HPO4
 pH is adjusted to 6.95, Filter sterilized, Stored at -20°C
5X RNA Running Buffer (for 500ml)
10 ml of 2M Sodium Acetate
10.3 gr MOPS
390 ml DEPC treated ddH2O are mixed and pH is adjusted to 7.0 with Sodium
Hydroxide
 5 ml, 0.5 M, pH. 8.0  EDTA is added.
Volume is completed to 500 ml with DEPC treated ddH2O.
4X RNA loading Buffer
50% formamide
20% Formaldehyde
15% 5X running buffer
15% glycerol-dye
in DEPC treated ddH2O. Stored at -20°C.
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DEPC H2O
1 ml DEPC in 1 L ddH2O
Stirred for 12 hours and autoclaved.
 50X TAE Buffer
2M Tris base
57.1 ml Glacial Acetic acid
50 mM EDTA
1X DNA loading buffer
0.25% bromophenol blue
0.25% xylene cyanole
50% glycerol
1mM EDTA
Ethidium bromide solution
10 mg/ml in water (stock solution)
30 ng/ml (working solution)
2.5   PRIMERS
       
           Annealing temperature
P73 C-terminal primers
P73-LF
(5’-GCCGGGATCCATATGGTGCCGCAGCCACTGGTGGAC-3’)           64°C
TT2-P73END
 (5’-CTCTCGAGAGTGGAT CTCGGCCTCCGTGAAC-3’)                       64°C
TA-p73 primers
1st set of primers (Fillipovich et al 2000)
Fillip-F
(5'-GGACGGACGCCGATGCC-3')             64°C
41
Fillip-R
(5'-GGTCCATGGTGCTGCTCAGC-3')             64°C
2nd   set of  primers
p73-VNF (Forward)
 (5’-CCAGGCCAGCCGGGACGGA-3’)                                                       64°C
p73-VNR (Reverse)
(5’-CTTGGCGATCTGGCAGTAGA-3’)                                                     64°C
 (Common reverse for both TA and DN Forms)
p73 DN form Primers
p73-DNF (New Forward) :
 (5’-GCTGTACGTCGGTGACCCC-3’)                                                      62°C
p73-VNR (Reverse)          :
  (5’-CTTGGCGATCTGGCAGTAGA-3’)                                                 62°C
GAPDH Primers (sayan et al 2001)
GAPD-F
(5’- GGCTGAGAACGGGAAGCTTGTCAT-3’)         62°C
GAPD-R 
(5’- CAGCCTTCTCCATGGTGGTGAAGA-3’)         62°C
P14 Primers (Sayan et al 2001)
p14ARF-F
(5’- TCACCTCTGGTGCCAAAGGG -3’)        62°C
C-R
5’- GGCAGTTGTGGCCCTGTAGG -3’)                                  63°C
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2.5.1 Alignment of the p73 primers on cDNA sequence of p73
        1 aggggacgca gcgaaaccgg ggcccgcgcc aggccagccg ggacggacgc cgatgcccgg
                                             p73-VNF    Fillip-F primer
       61 ggctgcgacg gctgcagagc gagctgccct cggaggccgg cgtggggaag atggcccagt
      121 ccaccgccac ctcccctgat gggggcacca cgtttgagca cctctggagc tctctggaac
      181 cagacagcac ctacttcgac cttccccagt caagccgggg gaataatgag gtggtgggcg
      241 gaacggattc cagcatggac gtcttccacc tggagggcat gactacatct gtcatggccc
(For only DN-p73)      accatgctg tacgtcggtg accccgcacg gcacctcgcc acg
                                 DN-p73 Forward
      301 agttcaatct gctgagcagc accatggacc agatgagcag ccgcgcggcc tcggccagcc
    Fillip-R primer
      361 cctacacccc agagcacgcc gccagcgtgc ccacccactc gccctacgca caacccagct
      421 ccaccttcga caccatgtcg ccggcgcctg tcatcccctc caacaccgac taccccggac
      481 cccaccactt tgaggtcact ttccagcagt ccagcacggc caagtcagcc acctggacgt
      541 actccccgct cttgaagaaa ctctactgcc agatcgccaa gacatgcccc atccagatca
      p73-VNR (common)
      601 aggtgtccac cccgccaccc ccaggcactg ccatccgggc catgcctgtt tacaagaaag
      661 cggagcacgt gaccgacgtc gtgaaacgct gccccaacca cgagctcggg agggacttca
      721 acgaaggaca gtctgctcca gccagccacc tcatccgcgt ggaaggcaat aatctctcgc
      781 agtatgtgga tgaccctgtc accggcaggc agagcgtcgt ggtgccctat gagccaccac
      841 aggtggggac ggaattcacc accatcctgt acaacttcat gtgtaacagc agctgtgtag
      901 ggggcatgaa ccggcggccc atcctcatca tcatcaccct ggagatgcgg gatgggcagg
      961 tgctgggccg ccggtccttt gagggccgca tctgcgcctg tcctggccgc gaccgaaaag
     1021 ctgatgagga ccactaccgg gagcagcagg ccctgaacga gagctccgcc aagaacgggg
     1081 ccgccagcaa gcgtgccttc aagcagagcc cccctgccgt ccccgccctt ggtgccggtg
     1141 tgaagaagcg gcggcatgga gacgaggaca cgtactacct tcaggtgcga ggccgggaga
     1201 actttgagat cctgatgaag ctgaaagaga gcctggagct gatggagttg gtgccgcagc
     1261 cactggtgga ctcctatcgg cagcagcagc agctcctaca gaggccgagt cacctacagc
          C-terminal Forward
     1321 ccccgtccta cgggccggtc ctctcgccca tgaacaaggt gcacgggggc atgaacaagc
     1381 tgccctccgt caaccagctg gtgggccagc ctcccccgca cagttcggca gctacaccca
     1441 acctggggcc cgtgggcccc gggatgctca acaaccatgg ccacgcagtg ccagccaacg
     1501 gcgagatgag cagcagccac agcgcccagt ccatggtctc ggggtcccac tgcactccgc
     1561 caccccccta ccacgccgac cccagcctcg tcagtttttt aacaggattg gggtgtccaa
     1621 actgcatcga gtatttcacc tcccaagggt tacagagcat ttaccacctg cagaacctga
     1681 ccattgagga cctgggggcc ctgaagatcc ccgagcagta ccgcatgacc atctggcggg
     1741 gcctgcagga cctgaagcag ggccacgact acagcaccgc gcagcagctg ctccgctcta
     1801 gcaacgcggc caccatctcc atcggcggct caggggaact gcagcgccag cgggtcatgg
     1861 aggccgtgca cttccgcgtg cgccacacca tcaccatccc caaccgcggc ggcccaggcg
     1921 gcggccctga cgagtgggcg gacttcggct tcgacctgcc cgactgcaag gcccgcaagc
     1981 agcccatcaa ggaggagttc acggaggccg agatccactg agggcctcgc ctggctgcag
    TT2-C-terminal Reverse
     2041 cctgcgccac cgcccagaga cccaagctgc ctcccctctc cttcctgtgt gtccaaaact
     2101 gcctcaggag gcaggacctt cgggctgtgc ccggggaaag gcaaggtccg gcccatcccc
     2161 aggcacctca caggccccag gaaaggccca gccaccgaag ccgcctgtgg acagcctgag
     2221 tcacctgcag aacc
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2.5.2  Expeceted band lengths of differnt variants in PCR Reactions:
N-Terminal Splice variants
TA-p73 form:
With first set of TA-p73 primers    : 290 bps
With second set of TA-p73 primers   : 553 bps
∆exon2 spliced form:
With first set of TA-p73 primers    : 171 bps
With second set of TA-p73 primers   : 433 bps
∆exon2-3 spliced form:
With second set of TA-p73 primers   : undetectable
With second set of TA-p73 primers   : 187 bps
DN-p73 Spilce-Variant   :   328 bps
C-Terminal Variants:
p73α (14 exons )                 : 766 bps
p73β (∆ exon 13)                 : 660 bps
p73γ (∆ exon 11)        : 617 bps
p73ε (∆ exons 11, 13)         : 510 bps
p73φ (∆ exons 11, 12)         : 478 bps
p73δ (∆ exons 11, 12, 13    : 382 bps
44
2.6      CELL LINES
Cell                               Status of Endogenous
Line               Origin                          p53             pRb              p16                 p14                  TA-p73                DN-p73          References
CAMA-1        Breast CA                    MT                +                   -ve                   +                      -ve                        -ve                      (i)
Saos-2            Osteosarcoma               -ve               -ve              +                    ?                          ?                           ?                       (ii)
Hep3B           HCC                             -ve               -ve                   +                    +                 +                        +                       (iii)
HepG2           HCC                            W T               +              +                    +                        +                        +                       (iv)
SK-Hep1        HCC                   WT                +      -ve            -ve         +             +                       (v)
SNU398           HCC                 -ve                  +           weak               +                 +             +                       (vi)
(i) Sayan E unpublished data; Ji et al, 1994.
(ii) Chandar et al 1992, Shew et al 1990; Spillare et al 1996.
(iii) Sayan et al, 2001; Puisieux et al, 1993.
(iv) Puisieux et al, 1993; Sayan et al, 2001; Hsu et al, 1993.
(v) Hsu et al, 1993; Sayan et al, 2001.
(vi) Sayan et al, 2001.
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CHAPTER 3
METHODS
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3.1        PREPARATION OF SUPER-COMPETENT CELLS
DH-5α E.coli strain was used to prepare super-competent cells. Glycerol
stock of DH5-α was grown overnight and diluted in 1 liter of SOB medium with a
starting absorbance of 0.2 at 600 nm. Then super-competent cells were prepared
as described in Inoue H et al 1990.
3.2  TRANSFORMATION
In super-competent cells 0.5 µg plasmid DNA was put and mixed with
tapping with fingers. After 30 minutes incubation on ice the cells were shocked in
42°C water bath for 90 seconds. Shocked cells were kept in ice for 2 minutes and
800 µl SOC medium was added on the cells. Following 1 hour incubation at 37°C
the cells were spread on antibiotic containing LB plates. Plates were incubated at
37°C for 16 hours and stored at +4°C for future use.
3.3  SMALL SCALE PLASMID ISOLATION (MINI-PREP)
Candidate colonies were inoculated in 5ml of LB medium with addition of
appropriate antibiotic. After incubation at 37°C overnight with shaking the 1.5 ml
of cultures was precipitated using micro-centrifuge. The cell pellet was
resuspended in 100µl Solution 1 (pre-lysis solution) with RNAase I. Then 200µl
Solution II (lysis buffer) was added and the tube was mixed gently by inverting
several times. Solution III (neutralization buffer) was added and the tube was
mixed gently by inverting several times. The mixture was kept on ice for 10
minutes and spinned at highest speed at 4°C for 10 minutes in micro-centrifuge.
The supernatant was transferred into new 1.5 ml eppendorf tube and 2 volumes of
cold absolute ethanol were added. Plasmid DNA was precipitated by centrifuging
at 4° with highest speed for 15 minutes in micro-centrifuge. Then supernatant was
discarded and pellet was washed once with cold 70% ethanol. The tube was left
on benchtop for drying. Dried pellet was dissolved in 50 µl of sterile ddH2O and
kept at -20°C.
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3.4  LARGE SCALE PLASMID ISLOATION (MAXI-PREP)
Bacterial cells were grown overnight at 37°C shaking incubator in 250 ml
LB with appropriate antibiotic. Grown cells were centrifuged and from the cell
pellet plasmid DNA was isolated using the QIAGEN maxi-prep kit as described
in the manual of the kit. Each batch of isolation yielded a DNA amount of nearly
500-1000 µg.
3.5  SPECTROPHOTOMETRIC QUANTIFICATION OF DNA
Concentration and purity of the DNA solutions were determined using
spectrophotometric measurement of the DNA samples. In new eppendorf tubes
the DNA samples were diluted in 100 Volumes of ddH2O  and measurements
were done using Beckman Instruments Du series 600 Spectrophotometer software
programs (ds DNA in Oligo DNA short methods) on the Beckman
Spectrophotometer Du 640 (Beckman Instruments Inc. CA. USA) at A260 and
A280.
3.6  STORAGE OF BACTERIAL CELLS
Cells were grown in LB medium containing appropriate antibiotic
overnight. In sterile 1.5 ml eppendorf tubes equal volumes of bacterial culture
and sterile 60% glycerol were mixed well using vortex. The mixture was stored at
–80°C.
3.7  CELL CULTURE
Mammalian cells were used as sources for RNA for RT-PCR analysis.
Cells were cultured in DMEM (Dulbecco’s Modified Eagle’s Medium)
supplemented with 10% Fetal Bovine Serum, 1mM L-Glutamine, non-essential
amino acids and penniciline/streptomycine (100units/ 100ug/ml) mix. Cells were
incubated at 37°C in an incubator with an atmosphere of 5% CO2 in air.
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Passage of the cells into new plates was done before reaching full
confluence. Old medium was aspirated and cells were washed once or more with
sterile 1X PBS. Trypsin was added on cell monolayer and incubated at 37°C for
20 seconds to 5 minutes depending on the cell type. Fresh medium was added on
the cells and cells were dispersed well by pipetting gently. Dispersed cells were
transferred into new dishes with new dilutions.
3.8 CALCIUM PHOSPHATE TRANSFECTION
In order to insert foreign DNA transiently into mammalian cells there are
several methods like electroporation, lipofection and calcium phosphate
transfection. For transient transfection the easiest way is the Calcium Phosphate
method if optimized well. The cells were subcultured into 100mm dishes 24 hours
before transfection aiming a confluency of 40% at transfection time. For this
purpose 250.000 to 350.000 cells were cultured in each 100mm plate depending
on the growth rate of the cell lines used. Transfections were done using 20µg
subject plasmid and 10µg pEGFP-N2 plasmid. The plasmid DNA was dissolved
in ddH20 and then 50µl 2.5M CaCl2 was added into the DNA solution drop by
drop while vortexing the solution. Calcium chloride-DNA mixture was kept at
room temperature for 30 minutes. During this time the mediums of the cells were
changed. At the end of 30 minutes, 500 µl of 2X BES solution was added into the
DNA-Calcium Chloride solution drop by drop while vortexing the solution. The
mixture and the cells were kept at room temperature and 37°C respectively for at
least 40 minutes. Then the DNA-Calcium Chloride-BES solution was spread on
cells drop by drop. Cells were incubated at 37°C for 12-16 hours depending on
the cell. The medium was changed. This time the cells were washed well before
adding new medium in order to get rid of all extra calcium chloride-DNA
complexes.
3.9  RNA ISOLATION
24 hour post-transfection the cells were washed with ice-cold PBS once.
350µl RA1 buffer of MN’s RNA isolation kit was added on cells and cells were
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scraped at 4°C. Lysates were put in RNAase-free eppendorf tubes and frozen
immediately in liquid nitrogen and kept at -80°C for future use. For isolation of
RNA from these lysates the procedure described in the manual of the kit was
followed. Only modification done was the usage of 250µl absolute ethanol
instead of 350 µl 70% ethanol added into the cell lysate. RNA samples were
frozen immediately in liquid nitrogen for future use. Before freezing, samples for
spectrophotometric and electrophoretic analysis were taken in separate tubes.
3.10  SPECTROPHOTOMETRIC QUANTIFICATION OF RNA
Concentration and purity of the RNA solutions were determined using
spectrophotometric measurement of the RNA samples. In new eppendorf tubes
the RNA samples were diluted in 100 Volumes of ddH2O (RNAse free) and
measurements were done using Beckman Instruments Du series 600
Spectrophotometer software programs (RNA measurement short methods) on the
Beckman Spectrophotometer Du 640 (Beckman Instruments Inc. CA. USA) at
A260 and A280.
3.11  AGAROSE GEL ELECTROPHORESIS OF RNA
SAMPLES
In 45 ml of 1X RNA running buffer 0.5 gram of agarose was dissolved.
After boiling it in microwave oven, 10ml of formaldehyde and Et-Br were added
and gel mixture was poured on the tray under hood in order to avoid
formaldehyde inhalation.
3.12  cDNA SYNTHESIS
For each synthesis reaction 3µg RNA was used. cDNA synthesis was
carried on as described in the MBI’s RevertAid first strand cDNA synthesis kit
manual. Synthesis products were diluted in 2 volumes of sterile ddH2O and stored
at –20˚C.
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3.13  POLYMERASE CHAIN REACTION
Quantitative PCR reactions were used to compare the number of copies of
a DNA fragment in a mixture. Before testing the samples the reaction should be
optimized for each fragment will be tested in samples. Optimizations for
GAPDH, p14, TA-p73, DN-p73, and C-terminal region of p73 PCRs were
previously done by Emre Sayan. Each reaction was done in 50µl total reaction
volume containing 5µl 10X PCR reaction buffer (NH4), 5 µl dNTP mix (2mM
stock), 3µl MgCl2 (2.5 mM stock), 1ul forward primer (25 picomolar), 1 µl
reverse primer (25 picomolar), 0.3 µl Taq Polymerase ( 1 units/µl), 1.5 ml
DMSO, and template DNA (amount depend on the fragment tested). cDNAs
prepared were used as template. The volume was completed to 50µl with ddH2O
The conditions for GAPDH PCR:
94˚C       5 minutes
94˚C       30 seconds
62˚C       30 seconds         24 cycles
72˚C       30 seconds
72˚C       5 minutes
The conditions for p14ARF PCR:
94˚C       5 minutes
94˚C       30 seconds
61˚C       30 seconds       30 cycles
72˚C       30 seconds
72˚C       5 minutes
Conditions for TA-p73 and
C-terminal region PCRs:
94˚C     5 minutes
94˚C     30 seconds
64˚C     30 seconds         35 cycles
72˚C     30 seconds
72˚C     5 minutes
The conditions for DN-p73 PCR:
94˚C      5 minutes
94˚C      30 seconds
62˚C      30 seconds         35 cycles
72˚C      30 seconds
72˚C      5 minutes
AGAROSE GEL ELECTROPHORESIS
1% agarose was prepared by dissolving enough agarose in 1X TAE buffer
and boiling in microwave oven. After adding Et-Br the gel was poured on tray
and left for polymerization. The gel in tray was embedded 1X TAE Buffer in the
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electrophoresis tank. Into the PCR products 10µl of 6X DNA loading buffer was
added and 10 µl of the samples was loaded in the wells. The samples were run at
80V for 40 minutes and gels were analyzed under BioRads transilluminator and
photographs of the gels were taken using the software MultiAnalyst of BioRad.
3.14   SEQUENCING OF DNA FRAGMENTS
3.14.1   ISOLATION OF DNA FRAGMENTS
PCR product was run in 1% agarose gel. The band corresponding to
subject fragment was spliced out the gel using a clean blade and put in 1.5 ml
eppendorf tube. The weight of the slice was measured. Isolation of the DNA from
the gel was carried out using the MN’s Gel-DNA isolation kit as described in the
manual of the kit.
3.14.2  PCR
Using the DNA purified from the gel as template a new PCR was carried
out using the conditions appropriate for the fragment of interest.
3.14.3  TA-CLONING
Promega’s TA-cloning kit was used to clone fragments produced by PCR.
Vector used was pGEM-T. The reaction mixture contained 50ng of vector DNA,
100ng of insert DNA, 7.5µl of 2X ligase buffer, and 3 units of T4 ligase supplied
in the kit. The mixture was incubated at room temperature for 2 hours and
supercompetent DH5-α bacterial cells were transformed using the whole ligation
product. Cells were spread on LB-agar plates containing ampicilline, IPTG and
X-gal. Plates were incubated in 37˚C incubator for 16 hours. White colonies were
selected as candidate clones and inoculated in fresh liquid LB medium containing
ampicilline.
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3.14.4  SCREENING OF COLONIES
Candidate clones were grown overnight and from the cultures plasmid
DNA was isolated using the manual mini-prep protocol as in section 3.3. 5µl
DNA samples of each clone were cut using appropriate restriction enzymes in
appropriate buffers. The restriction was carried out in a total volume of 20µl
containing 2µl 10X reaction buffer, 5µl DNA, 1µl specific restriction enzyme (1
units/µl) , and ddH2O. Mixture was incubated in 37˚C water bath for 2 hours and
whole restriction product was run on 1% agarose gel.
3.14.5 ISOLATION OF PLASMID DNA
For automated sequencing highly pure DNA is needed and for this purpose
the plasmid DNA isolation from candidate clones was done using MN’s plasmid
DNA isolation mini-prep kit as described in the manual. Mini-prep products were
run on agarose gel using a mass ruler to have an idea about the concentration of
the band. (Important for automated sequencing reactions)
3.14.6  AUTOMATED SEQUENCING
Automated sequencing was carried out by the technicians in our lab using
the kit. For each sequence reaction appropriate primers were diluted at least to a 1
pico molar concentration.
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CHAPTER 4
RESULTS
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4.1 SUMMARY OF RESULTS
Effect of E2F1 overexpression on p73 transactivation was demonstrated by
transient transfections followed by RT-PCR. For transfections plasmid DNA and
constructs were isolated from bacterial cells with maxi-prep. Concentrations of
plasmids were analyzed with spectrophotometry and compared with agarose gel
electrophoresis (section 4.2). 6 different cell lines were transfected with E2F1
construct together with pEGFP-N2 as an efficiency control. E2F4 transfections
and untransfected cells were used as negative controls. RNA and cDNA were
prepared from cells 24 hour after transfection. Templates were equalized with
GAPDH PCR (Section 4.4.2). As an indirect control of E2F1 expression p14ARF
PCR was done with HepG2 cell line samples (Section 4.4.3). Then PCRs were
done with C-terminal, TA-p73, and DN-p73 primers (Sections 4.4.4, 4.4.5, 4.4.6
respectively).
Time course activation of p73 isoforms were demonstrated on Cama-1
cells with transient transfection, followed by RNA isolation, cDNA synthesis and
p73 PCRs at 4 hour intervals. E2F1, TA-p73 and wt p53 transfections were done.
TA-p73 transfection was done to see whether DN-p73 was transactivated in
response to TA-p73. Wild type p53 was used as a positive control of p73 gene
transactivation; because it is known that it transactivates both TA-p73 and DN-
p73 promoters (Kartasheva et al 2002,).  GAPDH equalization, TA-p73 and DN-
p73 PCRs were done using cDNAs provided (sections 4.5.2, 4.5.3, 4.5.4
respectively).
The bands obtained from PCRs of TA-p73 were sequenced (section 4.6).
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4.2 PRODUCTION OF PLASMIDS AND CONSTRUCTS
pEGFP-N2, pCDNA3-TA-p73, pRC/CMV-E2F1, pRC/CMV-E2F4,
pRC/CMV-p53 vectors and constructs were transformed into super-competent
DH5-α bacterial cells. Transformed cells were grown overnight in 250 ml LB
with appropriate antibiotic. Using Qiagen’ s Maxi-Prep Kit, plasmid DNA from
these cultures were isolated as described in the kit’s manual. 3µl from each
sample were run on 1% agarose gel and concentrations of the plasmid solutions
were detected with spectrophotometric measurement.
Table 4: Spectrophotometric measurements of plasmid DNA samples
Sample Net Abs Net Abs 260/280 Dilution fa
Concentr
ation 
(ug/ml)
260 280
pCDNA3.1c 0.526 0.3036 1.73 100.00 2630.00
pEGFP-N2 0.4309 0.2542 1.70 100.00 2154.57
pCDNA3-TAp73 0.2466 0.1379 1.79 100.00 1233.10
pCMV-E2F1 0.3407 0.2038 1.67 100.00 1703.40
pCMV-E2F4 0.3524 0.2072 1.70 100.00 1704.99
pCMV-p53 0.2119 0.1175 1.80 100.00 1059.5
   M                 1                2             3               4            5                6
Figure 7: Agarose gel electrophoresis of Maxi-prep products in 1% gel. 5µl is
loaded from each sample.
Lanes:
M) Marker
1) pCDNA3.1.C, 2) pEGFP-N2, 3) pRC/CMV-p53, 4) pCDNA3-p73,
5) pRC/CMV-E2F1, 6) pRC/CMV-E2F4
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4.3  OPTIMIZATION OF TRANSFECTION
Saos-2, CAMA1, Hep3B and HepG2 cell lines grown in 60mm plates were
transfected with 1µg, 2µg, 5µg, 10µg and 30µg pEGFP-N2 vector. 16 hours post-
transfection medium of the cells were changed. 24 hour post-transfection
transfection efficiencies were observed under inverted fluorescence microscope.
It was seen that 30 µg DNA has the highest efficiency at each cell line and
did not harm the cells. In CAMA1 efficiency was over 50%. In Saos-2, Hep3B
and HepG2 efficiencies were 20%, 25% and 25% respectively.
4.4  ECTOPIC EXPRESSION OF E2F1 AND E2F4 AND THEIR
EFFECT ON TRANSCRIPTION OF P73 GENE.
Saos2, Cama1, Hep3B, HepG2, SK-Hep1, and SNU398 cells grown in
100mm plates were transfected together with 20µg E2F1 or E2F4 and 10µg of
pEGFP-N2. Extra plates of cells, which were not transfected, were grown as
negative control. Transfection efficiencies were as observed in optimization
experiment. For SK-Hep1 and SNU398 efficiency were lower than other cell lines
(20% and 10% respectively)
14 hour post-transfection the media of cells were refreshed. 24 hour post
transfection cells were scraped in RA1 buffer of MN’s nucleospin RNA isolation
kit and RNA isolation was done as described in the manual of the kit.
Spectrophotometric and gel electrophoresis analysis of the RNA samples were
done.
4.4.1    cDNA SYNTHESIS
3µg of RNA from each sample was used in cDNA synthesis. cDNA
synthesis was done using MBI’s RevertAid first strand cDNA synthesis kit as
described in the manual. Each cDNA product (20µl) was diluted in 2 volumes
(40µl) deionized water supplied with the kit.
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4.4.2     GAPDH PCR OF THE cDNA SAMPLES:
As a control of equal loading, a gene abundantly expressed in all cells is used. Here GAPDH gene was used. 2µl from each cDNA
sample was used as template and PCR reactions were done as described in methods.
Saos-2 Cama-1 Hep3B HepG2 SK-Hep1 SNU398
E2F1

+
 
+
 
+
 
+
 
+
 
+

E2F4
 
+
 
+
 
+
 
+
 
+
 
+ -ve
                 
Figure 8: GAPDH PCR. Using GAPDH PCR, templates were equalized for further semi-quantitative PCR reactions.
It is important to use equal amounts of cDNA as template in semi-quantitative PCR. Using GAPDH PCR the template amount for further
PCR reactions is equalized.
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4.4.3    P14ARF PCR FOR CHECKING THE EXPRESSION OF E2F1
 
p14ARF is one of the target genes transactivated by E2F1, so we used it as a control of E2F1 expression. Using 2µl from HepG2
samples as template p14ARF PCR were done in 50µl reaction volume. Conditions were as described in the methods. Each PCR product was
mixed with 10µl 6X DNA loading buffer and run on 1% agarose gel.
                         HepG2
   M         -ve      E2F1   E2F4
Figure 9: p14 ARF PCR of HepG2 samples.
Figure 9 shows that the cells have ectopic expression of E2F1. Increase in the amount of p14 transcript is due to the transcriptional
activation of p14 promoter by the expression of E2F1 gene exogenously inserted into the cells.
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4.4.4   PCR FOR p73 C-TERMINAL VARIANTS
7 µl from each cDNA sample was used in PCR in 50µl reaction volume using conditions described in methods. 6 µl of PCR
products were run on 1% agarose gel after mixing them with 10µl of 6X DNA loading buffer.
Saos-2 Cama-1 Hep3B HepG2 SK-Hep1 SNU398
E2F1

+
 
+
 
+
 
+
 
+
 
+

E2F4
 
+
 
+
 
+
 
+
 
+
 
+ -ve
              
Figure 10: PCR of samples for detection of C-Terminal Variants.
It is clear that expression of all C-terminal variants (there are six variants identified) are induced in response to E2F1 overexpression. E2F4
induces the expression of p73 relative to the untransfected controls but it is not as much as E2F1 does. The predominant form seems to be
the alpha p73 in all cell lines.
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4.4.5   PCR FOR TA-p73
7 µl from each cDNA sample was used in PCR in 50µl reaction volume using conditions for described in methods. 10 µl of PCR
products were run on 1% agarose gel after mixing them with 10µl of 6X DNA loading buffer.
Saos-2 Cama-1 Hep3B HepG2 SK-Hep1 SNU398
E2F1

+
 
+
 
+
 
+
 
+
 
+

E2F4
 
+
 
+
 
+
 
+
 
+
 
+ -ve
    A)      
    B)      
Figure 11: Transactivation of TA-p73 and two other N-terminal splice variants in response to E2F1 over-expression
Rows:
A) PCR using 1st  set of TA-p73 primers (Fillipovich et al 2001)
B) PCR using 2nd set of TA-p73 primers.
Figure 11-A and B are demonstrations of induction of TA-p73 and p73-∆exon2 forms in response to E2F1 overexpression. The upper
band in figure 11-A is TA-p73. However lower band was shown to be E2F1 instead of p73-∆exon2 form. In order to discard this
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parasite band we repeated the PCR reactions with new primer set in Figure 11-B. The two bands in B-panel was shown to be TA-p73
and p73-∆exon2 forms. The induction level of E2F1 is higher than E2F4 and untransfected controls. E2F4 has also a level of induction
higher than untransfected cells. The basal level of p73 forms differ in different cell lines. For example Cama-1 seem to have no p73
transcripts. Induction of E2F1 seem to induce both TA-p73 and p73-∆exon2 forms at equal amounts. On the other hand HCC cell lines
seem to express predominantly TA-p73 form. However expression of E2F1 induce both TA-p73 and p73-∆exon2.
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4.4.6            PCR FOR DN-p73
7 µl from each cDNA sample was used in PCR in 50µl reaction volume using conditions described in methods. 10 µl of PCR
products were run on 1% agarose gel after mixing them with 10µl of 6X DNA loading buffer.
Saos-2 Cama-1 Hep3B HepG2 SK-Hep1 SNU398
E2F1

+
 
+
 
+
 
+
 
+
 
+

E2F4
 
+
 
+
 
+
 
+
 
+
 
+ -ve
                 
Figure 12: DN-p73 PCR.
E2F1 transactivates DN-p73 form next to TA-p73 and p73-∆exon2 forms. Similar to TA-p73 PCR, there is basal expression of DN-
p73 form in HCC cell lines. Again E2F4 induced a level of DN-p73 relative to untransfected controls. E2F1 expression caused the highest
level of induction in DN-p73 form in SK-Hep1 cell line.
If summarized, it is absolute that E2F1 induces the expression of at least three p73 forms, two of which are dominant negative
forms.  However the basal levels and extent of induction of different p73 isoforms seem to be cell type specific.
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Table 5: Summary of sections 4.4.3-4.4.6; Induction of TA-p73, p73-Δexon2 and DN-p73 forms in  response to E2F1 overexpression.
 Cell Status of Endogenous               Untransfected                      E2F1 overexpression         E2F4 overexpression
 Line        Origin             53    pRb    p16    p14  TA-p73  p73-Δex2  DN-p73   TA-p73  p73-Δex2   DN-p73  TA-p73  p73-Δex2   DN-p73
Saos-2      Osteosarc.     -ve      -ve       +       +      ++            +              -ve          +              ++              +            +               +               +
CAMA-1  Breast CA      MT      +       -ve      +     -ve           -ve             -ve          ++            ++             ++           +               +               ±
Hep3B      HCC             -ve      -ve        +       +      ++       ±              -ve          ++++       +                ++          +++            ±              +
HepG2      HCC             WT      +       +      +       ++       ±              -ve          +++         +                ++          ++              ±               +
SK-Hep1  HCC              WT      +        -ve    -ve    +++       ±               +           ++++       +                +++        +++±         +               ++
SNU398   HCC     -ve        +     weak   + +++       ±             + +         +++±       +                +++        +++±         +               ++
Highlighted parts indicate that there is an increase.
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4.5  TIME-COURSE ACTIVATION OF P73 SPLICE VARIANTS
According to RT-PCR data done 24 hour post-transfection, it seems to be
both TA and DN forms of p73 are activated. However it may be biologically
important which form is activated first. If TA-p73 form is activated, then the
activation of DN-p73 form maybe a consequence of TA-p73 activation, because it
is known that one of the targets of activated TA-p73 protein is the DN-p73
promoter. On the other hand DN form can be a direct target of E2F1 transcription
factor and may be activated simultaneously or DN-p73 form may be activated
before TA-p73 form is activated. For this purpose we prepared 3 sets of cells for
p53 transfection, p73 transfection and E2F1 transfection. For each set 8 plates of
Cama-1 cells were splitted 24 hour before transfection (250.000 cells per plate).
These 8 plates were for harvesting cells post-transfection with different time
intervals (4hours, 8hours, 12hours, 16hours, 20hours, 24 hours, 36 hours, and 60
hours).  Transfections were done as described methods using 20µg of pRC/CMV-
p53 or pCDNA3-p73 or pRC/CMV-E2F1 together with 10µg of pEGFP-N2 as a
efficiency control. Efficiency of transfection was same in all plates (~60%). After
4hours, 8hours, 12hours, 16hours, 20hours, 24 hours, 36 hours, and 60 hours
post-transfection, at each time one plate from each three set was taken and the
media were aspirated. Cells were washed with cold PBS for 3 times and scraped
with 350µl of RA1 buffer of MN’s RNA isolation kit. RNA isolation was done
using the kit as described in the manual. Concentration of the isolated RNA
samples were measured using spectrophotometry with a dilution of 100 in DEPC
treated ddH2O.  RNA samples were run on agarose gel.
4.5.1     cDNA SYNTHESIS
Unfortunately some samples were not enough concentrated to do the
synthesis reactions with 3µg of RNA. So this time 2µg RNA was used in cDNA
synthesis reactions. Synthesis was carried on as described in the MBI’s RevertAid
first strand cDNA synthesis kit manual.
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4.5.2      GAPDH PCR OF THE cDNA SAMPLES:
3.5µl from each cDNA sample was used as template in PCR reactions
done as described in methods. 10 µl of PCR products were run on 1% agarose gel
after mixing them with 10µl of 6X DNA loading buffer.
Time M  0h 4h 8h 12h 16h 20h 24h 36h 60h -ve
A)   
B)   
C)   
Figure 13: GAPDH PCR of E2F1 (Row A), wt p53 (Row B), and TA-p73
(Row C) sets were used to equalize the template amounts for following PCR
reactions.
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4.5.3   TA-p73 PCR
Samples provided by the wt p53 and E2F1 transfections were used for TA-
p73 PCR. From each sample 11µl of cDNA was used as template in the PCR
reactions done as described in methods. Second set of TA-p73 primers were used.
10 µl of PCR products were run on 1% agarose gel after mixing them with 10µl
of 6X DNA loading buffer.
Time M  0h 4h 8h 12h 16h 20h 24h 36h 60h -ve
A)   
B)   
Figure 14: Time course transactivation of TA-p73 and p73-∆exon2 splice
variants of p73 in response to E2F1 (Row A) and wt p53 (Row B) over-
expression.
Arrows in figure 14-A show the TA-p73 and p73-∆exon2 forms (upper
and lower bands respectively). It is clear that there is a time dependent increase in
transcription of both forms in response to E2F1 overexpression. The transcripts
can be detected at 4th hour. Induction makes a peak at 12th hour and a second peak
at 36th hour. A similar pattern with a lower intensity of bands can be seen in wt
p53 overexpression instead of E2F1 (Figure 14-B). Effect of TA-p73 was not
tested due to technical problems.
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4.5.4  DN-p73 PCR
Samples of all 3 sets (E2F1, TA-p73 and wt p53 transfections) were tested
for activation of DN-p73 using 11µl of cDNA as template. Conditions were as
described in methods. Products were run on 1% agarose gel.
Time M  0h 4h 8h 12h 16h 20h 24h 36h 60h -ve
A)     
B)     
C)     
Figure 15: Time-course transactivation of DN-p73 splice variant in response to
E2F1 (Row A), wt p53 (Row B), and TA-p73 (Row C) over-expression in Cama1
cells. Arrow shows a specific cross-reacting band, which is most probably TA-
p73.
Arrows in Figure 15-A and B shows the DN-p73 bands induced in
response to E2F1 and wt p53 overexpression respectively. DN-p73 transcripts are
detectable at 8th hour after E2F1 expression. The pattern in wt p53 overexpression
is same but the intensity of bands is significantly higher than E2F1. DN-p73
induction makes peak at 36th and 24th hours after E2F1 and wt p53 expression
respectively. TA-p73 also induces transcription of DN-p73 (lower bands with
arrow in Figure 15-C). However DN-p73 primers specifically cross-reacted with
ectopic TA-p73 that there are parasite bands (upper bands with arrow in figure
15-C) However it can be seen that DN-p73 is induced in response to TA-p73at 4th
hour.
As a summary Figures 14 and 15 demonstrates the time-course activation
of TA-p73, p73-∆exon2, and DN-p73 in response to E2F1, wt p53 and TA-p73
overexpression. DN-p73 is induced with four hours later than TA-p73 is induced
in response to E2F1. TA-p73 and p73-∆exon2 forms are induced together and at
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equal amounts. Wt p53 is capable of inducing both TA-p73 and DN-p73. TA-p73
induces DN-p73 induction.
Table 6: Time course activation of TA-p73, p73-Δexon2 and DN-p73 forms in
response to E2F1, wt p53 and TA-p73 overexpression.
          TRANSFECTIONS
  E2F1 wt p53 TA-p73
TA-p73 0h ± -ve N.D.
 4h + ± N.D.
 8h ++ + N.D.
 12h +++ +± N.D.
 16h +++ +± N.D.
 20h +++ +± N.D.
 24h +++ ++ N.D.
 36h ++++ +± N.D.
 60h ++ + N.D.
 Start of induction 4th hour 4th hour N.D.
 Peak at 12th hour, 36th hour 24th hour N.D.
     
p73-
Deltaexon2 0h ± -ve N.D.
 4h + ± N.D.
 8h ++ + N.D.
 12h +++ + N.D.
 16h +++ + N.D.
 20h +++ + N.D.
 24h +++ + N.D.
 36h +++ + N.D.
 60h ++ + N.D.
 Start of induction 4th hour 4th hour N.D.
 Peak at 12th hour 16th hour N.D.
     
DN-p73 0h -ve -ve -ve
 4h -ve -ve ±
 8h ± ± ±
 12h ± + +
 16h + + ±
 20h + ++ ++
 24h + +++ ++
 36h ++ ++ +
 60h + + +
 Start of induction 12th hour 8th hour 4th hour
 Peak at 36th hour 24th hour 20th hour
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4.6    SEQUENCING OF THE BANDS PROVIDED
          BY THE PCR REACTIONS
After the PCR products were run, the bands for sequencing were spliced
out and purified. A second PCR was done with these purified products using
same primers. For sequencing either the purified PCR product or the constructs
made by cloning these PCR products into pGEM-T vectors were used.
The extra band amplified by 1st set of TA-p73 primer was found to be
E2F1, not ∆exon2 spliced form of p73 as we thought (Figure 11, Row A, lower
band). Surely this does not mean that there was not any amplified ∆exon2 spliced
form of p73. The amplified E2F1 parasite band had exactly the same length that it
should have masked the p73Deltaexon2 spliced form either on the gel or in PCR
reaction by competition. With a new set of TA-p73 primers the PCR reactions
were repeated (Figure 11, Row B) and the new bands were sequenced. They were
confirmed to be TA-p73 and p73-∆exon2 forms.
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CHAPTER 5
DISCUSSION
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DISCUSSION
Our data demonstrate that in all cell lines used, transcription of at least
three N-terminal variants of p73 is induced in response to E2F1 over-expression.
E2F1 was successfully expressed in cells after transient transfection, as
demonstrated by p14ARF PCR (Figure 9).  Figure 10 shows that all C-terminal
variants of p73 were induced; being the alpha form the abundant one. E2F4
expression caused also a degree of increase in p73 transcripts but, it was not as
dramatic as E2F1 did. First set of TA-p73 primers (Fillippovich et al 2001)
showed increase in two bands corresponding to TA-p73 and p73-∆exon2 forms in
response to E2F1 expression ( higher and lover bands respectively) (Figure 10).
However, sequencing analysis revealed that this band was E2F1. Interestingly the
primers have more than 50% homology to different regions on E2F1, resulting in
parasite bands, which should have masked the p73-∆exon2 form by either
competing in PCR or blocking its view on the gel. In order to avoid parasite
bands we designed another primer set which could detect three forms of 73; TA-,
∆exon2, and ∆exon2-3 forms. Semi-quantitative PCR with these primers revealed
similar results as first set of primers. It was also shown that obtained bands were
TA-p73 and p73-∆exon2 forms with sequence analysis. Expression of both TA-
p73 and p73-∆exon2 forms were induced in response to E2F1 with respect to
untransfected and E2F4 transfected controls. Interestingly there was another band
smaller than two forms, which maybe the p73-∆exon2-3 form induced in both
E2F1 and E2F4 transfections of Cama-1 cells (Figure 11, Row B, Cama-1
lanes). In addition, basal and E2F1 induced levels of TA-p73 and p73-∆exon2
expressions were different in different cell lines. HCC cell lines have
predominantly TA-p73 form. There was not a basal expression in Cama-1 and
E2F1 caused expression of equal amounts of TA-p73 and p73-∆exon2 transcripts.
 It is very clear that DN-p73 is transactivated in all cell lines with E2F1
over-expression (Figure 12). Similar to TA-p73, different cell lines have
different basal expression levels of DN-p73 form. HCC cell lines had basal
expression of DN-p73, whereas untransfected Cama-1 was negative of DN-p73
expression. E2F1 expression resulted in induction of transcription of DN-p73,
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which was not demonstrated before. E2F4 caused an increase in Cama-1, HepG2,
and Hep3B less than E2F1. There is a possibility that this DN-p73 transactivation
was not a direct effect of E2F1. It was shown before that DN-p73was
transactivated by TA-p73 and induction of DN-p73 in our data may be a
consequence of TA-p73 transactivated by E2F1. A semi-quantitative RT-PCR
after cycloheximid treatment of E2F1 transfected cells may reveal whether DN-
p73 is a direct target of E2F1.
For determination of cell fate, whether proliferation, cell cycle arrest or
apoptosis will be induced the timing of proliferative and anti-proliferative signals
is very important. The way the cell will be forced may be different depending on
the form of p73 activated first. In a time-course transactivation experiment, we
demonstrated the transactivation of DN-p73, TA-p73 and p73-Delta-exon2 forms
in 4 hour intervals, in order to see the sequential activation of different forms. As
controls we used wt p53 and TA-p73 transfections. E2F1 expression resulted in a
continuous increase in the transactivation of both TA-p73 and p73-∆exon2 forms
starting from 4th hour, and making a peak at 36th hour (Figure 14. Row A).
Interestingly the band intensities of two forms seem to be equal, and this may
mean that nearly equal amounts of TA-p73 and p73-∆exon2 proteins are induced
by E2F1 in cells, neutralizing each other. Transactivation of DN-p73 seems to be
activated at 8th our after E2F1 transfection (Figure 15, Row A). TA-p73 and wt
p53 could transactivate DN-p73 starting at 8th and 4th hours respectively (Figure
15, Rows B and C). Effect of TA-p73 on DN-p73 expression strengthens the
possibility that DN-p73 activation in response to E2F1 might be mediated by TA-
p73, however it should be tested.
 Actually if there was not an activation of p73-∆exon2 form, we could
conclude that 4 hour earlier activation of TA-p73 than DN-p73 form could guide
the cell to apoptosis or cell cycle arrest. However transactivation of equal amount
of p73-∆exon2 form maybe be the early inhibitor of TA-p73 before DN-p73 form
is transactivated. If TA-p73 is inhibited by p73-∆exon2, activation of DN-p73
transcription might be a direct effect of E2F1 or indirect effect of E2F1 using
other mediators rather than TA-p73.
 Our wt p53 controls showed that TA-p73, p73-∆exon2 and DN-p73 forms
were transactivated in response to wt p53 over-expression (Figure 14 row B,
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Figure 15 row B respectively). When compared with E2F1 transfection (Figure
14 row A), wt p53 induced transactivation of TA-p73 weaker than E2F1 did
(Figure 14 row B). However transactivation of DN-p73 by wt p53 was stronger
than E2F1 (Figure 15 rows A, B) confirming a recent data about targeting of wt
p53 to DN-p73 promoter (Kartasheva et al 2002).
 E2F1 protein has proliferative and anti-proliferative functions. This seem
to be one of the paradoxes not yet have been solved. There are other molecules
seem to have dual functions such as Myc and E1A.  E2F1 was shown to induce
activation genes involved in proliferation (cell cycle regulation, DNA replication)
and apoptosis. Correlating with activation of this variety of genes, E2F1 was
shown to induce either proliferation or apoptosis in different systems. It was
shown that it induced S-phase entry and DNA synthesis (Johnson et al 1993; Vigo
et al 1999). G1 phase blocks induced by pRb, CKIs, TGF-Beta, and gamma-
irradiation were overcome by E2F1 overexpression (Zhu et al 1993; DeGregori et
al 1995; Lucas et al 1996; Schwarz et al 1995). Together with Ras activation
E2F1 deregulation transformed primary Rat fibroblast cells (Johnson et al 1994).
In different conditions E2F1 overexpression induced apoptosis (Wu et al 1994,
Qin et al 1994; Kowalik et al 1994; Lissy et al 2000; Stiewe and Putzer 2000;
Irwin et al 2000). Both positive and negative effects on tumor development were
seen in response to absence or presence of E2F1 (Johnson 2000).  Similarly p73
gene encodes different proteins working as antagonist of each other. While TA-
p73 transactivates apoptotic genes, DN-p73 inhibits TA-p73 via hetero-
oligomerization. Consequently p73 gene seems to encode both a tumor-
suppressor and an oncogene.
There are models proposed to solve the paradox of activation of both
proliferative and apoptotic signals by the same factor. Previously it was proposed
that the induction of apoptosis by proliferative factors was a reaction of cell to the
unscheduled and abnormal cell cycle progression. This model depends on the
activation of apoptosis by conflicting growth signals. However another model
suggests that induction of apoptosis is a normal consequence of cell cycle
progression (Harrington et al 1994). This model couples the signals inducing cell
cycle and apoptosis. Stimulation of cells to enter cell cycle promotes apoptosis at
the same time. However the fate of the cell is determined later by additional
apoptotic and proliferative signals. This model is supported by experiments on
74
different systems, in which change of same parameter led to both apoptosis and
proliferation, most probably because of different sets of factors in these different
systems deciding the fate of the cell in addition to the first stimulating factor.
Correlating with this model, E2F1 activated both apoptotic and antagonist p73
forms in our experiments.  Interestingly the basal levels of these forms were
different in different cell lines demonstrating that there are other factors deciding
the final fate of cell in addition to the E2F1 itself. The activation extent of
activating and dominant negative forms in response to E2F1 was different in
different cell lines. For example TA-p73 form was abundantly expressed in HCC
cell lines and E2F1 induction increased TA-p73 more than other forms. Although
dominant negative forms were increased too, they were not as much as TA-p73
form. This means abundant TA-p73 may induce activation of apoptosis despite
the presence of dominant negative forms, which are present in lower amounts.
However, still other factors such as presence of mutant p53 may inhibit TA-p73
(Di Como et al 1999). On the other hand, Cama-1 cells had no p73 transcript in
untransfected state. E2F1 induction led to a similar amount of increase in TA-p73
and p73-∆exon2 forms. In addition, DN-p73 form was induced. Total amount of
dominant negative form transcripts were higher than TA-p73 forms. In these cells
activation of p53 and TA-p73 induced apoptosis or cell cycle arrest by E2F1 may
be inhibited by the dominant negative forms.
Activation of both proliferative and apoptotic pathways by the same factor
give the cell the chance to select one of the ways easily depending on the status of
the cell and other factors found in the cell. If the cell is not ready for a following
division, the cells may enter cell cycle arrest and provide time for cells to check
for problems and get ready. If the cells can get ready and repair themselves in this
time the cells are committed to enter cell cycle by extra factors and the
commitment of apoptosis is cancelled with activation of additional anti-apoptotic
signals.  If there are problems those can not be recovered cells are led to
apoptosis. Such a scenario is supported with our data demonstrating that the
different forms of p73 were sequentially activated in response to E2F1 induction.
Time-course induction of E2F1 induced DN-p73 form 8 hours later than it
induced TA-p73 from. TA-p73 form may cause a cell cycle arrest in cells to
provide time for cells to get ready and decide whether to go division or apoptosis.
If the cells are ready for division activation of DN-p73 eight hours later, helps the
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cells to recover cell cycle arrest caused by TA-p73 and additional factors induce
cell cycle progression. If the cell decides to go apoptosis additional apoptotic
signals are activated and the effect of DN-p73 activated later is diminished,
leading cells to apoptosis.
It is necessary to think about the other pathways induced by E2F1
overexpression. Being a transcription factor there are many genes seem to be a
target of E2F1. It can be a big mistake thinking activation of p73 gene
independent of other pathways. P53 was shown to be directly and indirectly
activated by E2F1. The indirect effect is mediated by p14ARF, which prevents
MDM2 to target p53 to proteolysis. Direct effect of E2F1 on p53 was shown to be
by direct protein-protein binding, in the absence of cyclin A. This binding
stabilized p53 and induced apoptosis (Hsiesh et al 2002). In addition to
stabilization and activation of p53 the activation of dominant negative p73 forms
by E2F1, maybe a safeguard mechanism to balance the apoptotic and proliferative
signals for the sake of cell, as it was shown before that p53 was a target of
dominant negative p73 forms (Pozniak et al 2000).
The status of the p53 in the cells is also important in determination of cell
fate in response to activation of p73 forms with E2F1 overexpression. Several
mutant forms of p53 are capable of blocking TA-p73 (Di Como et al 1999).
Presence of such mutants in cells may act as inhibitors of TA-p73 induced
apoptosis.
In cancer development deregulation of such dual mechanisms may play
important roles. Induction of both proliferative and anti-proliferative signals at
the same time by the same factor may be advantageous to cells to develop cancer
if somehow they discard the apoptotic signals despite the abnormalities in the
cell. The presence of acquired expression of TA-p73 gene in cancer cells may be
a consequence of such a dysregulation (Sayan et al 2001). These cells are
resistant to apoptosis although they seem to have excess amount of TA-p73
transcripts which are not present in normal tissues the cancer cells are derived
from. Expression of dominant negative forms in addition to TA-p73 form in
response to oncogenic activation may be the fact that these cancer cells tolerate
TA-p73 mediated apoptosis. Another mechanism can be the generation of p53
mutants which can inhibit TA-p73. Previous study by Sayan et al demonstrated
such a correlation between p73 and mutant p53 (Sayan et al 2001). Our data may
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suggest that expression of dominant negative forms may be another mechanism
cancer cells use to prevent TA-p73 or wt p53 induced apoptosis.
Interestingly there are a few mutations of p73 gene in thousands different
cancer samples analyzed, conflicting with the idea that p73 is a tumor suppressor.
However, it is not abnormal that a gene encoding both proliferative and anti-
proliferative or apoptotic and anti-apoptotic protein products, does not show
mutations in cancers. Presence of dual roles may give advantages to cancer cells.
Such genes maybe more useful if not mutated for cancer cells. Similarly p73 gene
which is not mutated and capable of encoding anti-apoptotic products may be
more advantageous than a mutated one.
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CHAPTER 6
CONCLUSION
AND FUTURE
PERSPECTIVES
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6.1    CONCLUSION
Transactivating p73 was the only form shown to be transactivated by E2F1
overexpression previously. Consequence of TA-p73 activation in p53-/- was
shown to be apoptosis in response to exogenous E2F1 expression (Lissy et al
2000; Irwin et al 2000; Stiewe and Putzer 2000). Confirming the previous data,
we demonstrated the induction of TA-p73 in six different cell lines. The striking
data we present is the induction of two extra forms of p73 by E2F1. Interestingly,
these two forms, p73-∆exon2 and DN-p73 lack the transactivation domain of TA-
p73 and so are called dominant negative forms. Their function is thought to be the
inhibition of TA-p73 and p53 by hetero-oligomerization.
Although it was shown to induce apoptosis when overexpressed, E2F1
may cause different results in different cell lines depending on the sequential
activation of different p73 forms. According to data obtained from time-course
activation of p73 forms in response to E2F expression, DN-p73 form seem to be
induced 4 hour later than TA-p73 and p73-∆exon2 forms. Presence of ∆exon2 and
DN-forms may inhibit the activity of TA-p73. Induction of cell cycle arrest or
apoptotic genes by TA-p73 may be blocked by the dominant negative forms.  In
normal cells mostly, important effects for cell life are balanced with anti-effects.
For example, p53 is activated in response to several stimuli including DNA-
damage and induce apoptosis. Interestingly it also activates its negative regulator
MDM2, which targets it to proteolysis. By this way such important signals kept
transient and balanced well. If the cell can repair itself, apoptotic signal is
cancelled. Sequential activation of p73 forms may have a similar role. In response
to oncogenic activation such as E2F1, immediate response may be the TA-p73
transactivation, which may induce cell cycle arrest or apoptosis. After a certain
time the antagonist of TA-p73, DN-p73 may be induced to balance the effect of
TA-p73 and provide time for cells to repair themselves before entering apoptosis.
Such a dual p73 transactivation in response to oncogenic activation may
be an advantageous strategy of cancer cells to overcome TA-p73. Actually it was
shown before that cancer cells have an acquired TA-p73 expression (Sayan et al.
2001). However these cells were resistant to apoptosis, which should be activated
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by prolonged TA-p73 activation. This resistance may be mediated by expression
of dominant negative forms of p73 next to TA-p73 in response to oncogenic
activation.
As a conclusion, dominant negative forms p73 are transactivated with TA-
p73 in response to exogenous E2F1 expression, with an eight hour interval. Such
a sequential activation may provide normal cells to respond oncogenic activation
with cell cycle arrest and balance it with DN-p73 forms to give cells enough time
for repair. Deregulation of this mechanism maybe advantageous for cancer cells
to overcome apoptotic effects of prolonged TA-p73 activation.
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6.2       FUTURE PERSPECTIVES
The most important question after demonstration of sequential activation
of p73 forms in response to E2F1 expression is the consequences of this
sequential activation for cells. We proposed that TA-p73 activated earlier than
DN-p73 may induce cell cycle arrest, which may finally end with apoptosis. Later
activation of DN-p73 may inhibit TA-p73 and provide time for cells to repair
damages or to overcome oncogenic activation. In order to see this, the cells
transfected with E2F1 should be observed in different time intervals to see
whether they are arrested correlating with TA-p73 transactivation. The effect of
later DN-p73 activation on cell cycle arrest may be seen whether DN-p73
weakens the effect of TA-p73 or not.
In order to distinguish the direct effect of E2F1 on DN-p73 promoter, a
cycloheximid treatment can be done after E2F1 transfection and semi-quantitative
PCRs for DN-p73 can be repeated. Cycloheximid is an inhibitor of translation. As
far as the E2F1 protein is supplied the endogenous TA-p73 gene is transcribed
but not translated, so if there is still induction of DN-p73 this means that E2F1
can directly activate DN-p73 promoter.
Mutant forms of p53 may be used to inhibit TA-p73 instead of
cyloheximid treatment. E2F1 transfection of cell lines having mutant p53 or co-
transfection of E2F1 with mutant p53 may be done and activation of DN-p73 may
be tested with semi-quantitative RT-PCR
In order to demonstrate the activation of p73 in protein level, the western
blot and immuno-fluorescence experiments can be done.
As a functional study, cell lines other than Saos-2, which respond TA-p73
transfection with apoptosis may be used to see the effect of E2F1 on apoptosis in
different backgrounds. This may also show the effect of E2F1 on cell fate
determination, when it transactivated different sets of p73 isoforms in different
cell lines. A double staining of p73 and Annexin V or NAPO (Sayan BS et al
2001) can reveal in these cell lines whether p73 transactivation is co-localizing
with apoptosis.
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Construction of stable transformants of inducible E2F1 may be another
choice to see the effect of E2F1 in 100% of cells, rather than transient
transfections.
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